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ABSTRACT 
 
The flaxseed lignan, secoisolariciresinol diglucoside (SDG), and its aglycone, 
secoisolariciresinol (SECO), have demonstrated benefits in the treatment and/or 
prevention of cancer, diabetes and cardiovascular disease.  In order for the lignans to be 
used therapeutically, the safety of administration alone and in conjunction with other 
drugs must be determined.  The primary cause of drug interactions is induction and 
inhibition of cytochrome P450 (CYP) and phase II enzymes.  A preliminary screen was 
conducted to assess the potential for SECO and SDG to cause CYP inhibition.  A 
method was established to assess for CYP, glutathione-S-transferase (GST) and uridine 
diphosphate-glucuronosyltransferase (UGT) induction in rat primary hepatocytes by 
real-time reverse transcription-polymerase chain reaction (RT-PCR). 
Preliminary assessments of inhibition measured the metabolism of testosterone to 
6β-, 16α- and 2α-hydroxytestosterone, which corresponds to CYP3A, 2B/2C11 and 
2C11 enzyme activity in rat hepatic microsomes by a validated high performance liquid 
chromatography (HPLC) method.  Irreversible inhibition studies found that SDG is not 
an inhibitor of these isoforms up to 1000 μM.  Secoisolariciresinol caused reversible 
inhibition of 6β-hydroxytestosterone at all testosterone concentrations, with an IC50 
(inhibitor concentration causing 50% inhibition of enzyme) between 400 and 800 μM.  
Over the range of SECO concentrations tested, 10 – 1600 μM, 6β-hydroxytestosterone 
formation was reduced to 95 – 29% of control levels at 50 μM testosterone.     
Secoisolariciresinol caused a concentration-dependent increase in 16α-
hydroxytestosterone formation at 50 μM testosterone.  At 10 μM SECO, there was 90% 
of control activity, but at 1600 μM metabolite formation was 172% of control.  The 
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formation of 2α-hydroxytestosterone was not affected at any testosterone or inhibitor 
concentration.  Thus, SECO appears to be a CYP3A inhibitor and a CYP2B activator at 
testosterone KM levels.  The mechanism of reversible inhibition could not be determined 
due to the possibility of non-Michaelis-Menten kinetics observed with CYP3A 
inhibition and CYP2B activation.   
The gold standard in vitro model to assess induction is primary hepatocytes.  A 
method was established that allowed for the isolation and culture of these cells.  Positive 
controls caused induction of CYP mRNA levels after 24 hours treatment, demonstrating 
the ability of enzyme induction in the test system.  Primers for real-time RT-PCR were 
designed that amplified CYP1A1, 1A2, 2B1, 2C11, 2C13, 2D1, 2D2, 3A1 and 3A2, 
GSTA2, A5 and P1, and UGT1A1, 1A7, 1A8, 2B1 and 2B12 genes.  A preliminary 
assessment of transcriptional upregulation of drug metabolizing enzymes by SECO and 
SDG can be assessed in isolated and cultured rat primary hepatocytes.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv
ACKNOWLEDGEMENTS 
 
 I would like to acknowledge the support of my supervisors Dr. Jane Alcorn and 
Dr. Ed Krol.  They were committed to my project and my development as a scientist.  I 
would like to specifically thank Dr. Alcorn for her guidance academically and otherwise.  
She was always available to answer questions and required me to examine everything 
and develop my own scientific skills.  I would also like to thank the other members of 
my committee: Dr. David Janz and Dr. Barry Blakley for their consistent support and 
my external examiner Dr. Andrew Olkowski.  Funding for this research was generously 
provide by the Natural Sciences and Engineering Research Council of Canada. 
 I would like to thank Dr. Harry Deneer for the use of the SmartCycler, Gloria 
Woo for her assistance with animal surgery and all the summer students for their 
assistance.  I would also like to thank the members of the Alcorn/Krol lab group: Fawzy 
Elbarbry, Brian Fahlman, Katie Maloney and BinBing Ling for providing academic and 
social support throughout the entire project.  Thank you for teaching me the scientific 
skills needed to complete my degree.   To Jennifer Billinsky, thanks for all your tireless 
support and assistance in helping me through my research.  Without Dr. Alcorn and 
Jennifer Billinsky constantly challenging my development, this research would not have 
been possible.      
 Finally, to Mandy Lee Olsgard, for always listening, always supporting and 
always being there.  I am eternally grateful.     
 
 
 
 
 
 
 v
DEDICATION 
 
 This thesis is dedicated to all my friends and family.  In particular, I would like 
to dedicate this thesis to my parents, Dorothy Anne Russell Reid Boyd and Kenneth 
Larry Boyd, whose constant love, support and guidance have been my inspiration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
TABLE OF CONTENTS 
Page 
PERMISSION TO USE ................................................................................................. i 
 
ABSTRACT................................................................................................................... ii 
 
ACKNOWLEDGEMENTS ........................................................................................... iv 
 
DEDICATION ............................................................................................................... v 
 
TABLE OF CONTENTS............................................................................................... vi 
 
LIST OF TABLES ......................................................................................................... xi 
 
LIST OF FIGURES ....................................................................................................... xiii 
 
LIST OF ABBREVIATIONS........................................................................................ xv 
 
CHAPTER 1 .................................................................................................................. 1 
1. Literature Review....................................................................................................... 1 
1.1 Introduction........................................................................................................... 1 
1.2 Natural Health Products ........................................................................................ 2 
1.2.1 Natural Health Products – An Introduction ................................................. 2 
1.2.2 Natural Health Products and Consumer Use/Attitudes in Canada............... 2 
1.3 Flaxseed ............................................................................................................... 3 
1.3.1 Components and Growth ............................................................................. 3 
1.3.1.1 Flaxseed Industry ............................................................................. 3 
1.3.1.2 Flaxseed Components ...................................................................... 3 
1.3.2 Health Benefits Related to the Flaxseed Lignans ........................................ 4 
1.3.3 Status of Flaxseed as a Natural Health Product ........................................... 5 
1.3.4 Plant and Mammalian Lignan Pharmacokinetics......................................... 5 
1.3.4.1 Absorption and Intestinal Metabolism in Rats ................................ 7 
1.3.4.2 Oxidative and Phase II Metabolism in Rats..................................... 7 
1.3.4.3 Distribution in Rats .......................................................................... 8 
1.3.4.4 Excretion in Rats .............................................................................. 8 
1.3.4.5 Enterohepatic Circulation................................................................. 8 
1.3.4.6 Lignan Pharmacokinetics in Humans .............................................. 9 
1.3.5 Toxicity ....................................................................................................... 9 
1.4 Drug Metabolizing Enzymes ................................................................................ 10 
1.4.1 Cytochrome P450 and Phase II Enzymes .................................................... 10 
1.4.1.1 Cytochrome P450............................................................................. 10 
1.4.1.2 Uridine Diphosphate-Glucuronosyltransferase................................ 10 
1.4.1.3 Glutathione-S-Transferase ............................................................... 12 
1.4.2 Induction of Drug Metabolizing Enzymes................................................... 12 
1.4.2.1 Mechanisms of Induction................................................................. 12 
1.4.2.2 Cytochrome P450............................................................................. 13 
 vii
1.4.2.3 Uridine Diphosphate-Glucuronosyltransferase................................ 13 
1.4.2.4 Glutathione-S-Transferase ............................................................... 14 
1.4.2.5 Induction Cross-Over Between Drug Metabolizing Enzyme 
Families ........................................................................................................ 14 
1.4.2.6 Natural Products as Inducers............................................................ 15 
1.4.3 Inhibition of Drug Metabolizing Enzymes .................................................. 17 
1.4.3.1 Mechanisms of Enzyme Inhibition .................................................. 17 
1.4.3.2 Cytochrome P450............................................................................. 18 
1.4.3.3 Uridine Diphosphate-Glucuronosyltransferase................................ 18 
1.4.3.4 Glutathione-S-Transferase ............................................................... 19 
1.4.3.5 Natural Products as Inhibitors.......................................................... 19 
1.4.4 Natural Product Drug Interactions ............................................................... 20 
1.5 Lignans as Inducers and Inhibitors of Drug Metabolizing Enzymes.................... 20 
1.5.1 Induction of Cytochrome P450 and Phase II Enzymes................................ 20 
1.5.2 Inhibition of Cytochrome P450 and Phase II Enzymes ............................... 23 
1.6 Methods of Assessment of Induction and Inhibition of Drug 
Metabolizing Enzymes by the Plant Lignans In Vitro .......................................... 23 
1.6.1 Model Systems Used in the Assessment of Drug Metabolizing 
Enzyme Effects ............................................................................................ 23 
1.6.1.1 Rat Primary Hepatocytes ................................................................. 23 
1.6.1.2 Microsomes ...................................................................................... 24 
1.6.2 In vitro Assessment of Induction of Drug Metabolizing Enzymes.............. 24 
1.6.2.1 Real-time Reverse Transcription – Polymerase Chain 
Reaction ........................................................................................... 24 
1.6.2.2 Cytochrome P450, Uridine Diphosphate-
Glucuronosyltransferase and Glutathione-S-Transferase 
Gene Targets for Induction .............................................................. 26 
1.6.3 In vitro Assessment of Inhibition of Drug Metabolizing Enzymes ............. 26 
1.6.3.1 Activity Assays ................................................................................ 26 
1.6.3.2 Cytochrome P450, Uridine Diphosphate-
Glucuronosyltransferase and Glutathione-S-Transferase 
Isoforms as Targets for Inhibition.................................................... 27 
1.7 Model Animal System .......................................................................................... 27 
1.7.1 Ease of Handling and Extrapolation ............................................................ 27 
1.7.2 Pharmacokinetics and Pharmacodynamics of Plant Lignans....................... 28 
 
CHAPTER 2 .................................................................................................................. 29 
2. Purpose of Project ...................................................................................................... 29 
2.1 Rationale ............................................................................................................... 29 
2.2 Objectives.............................................................................................................. 29 
2.2.1 Objective 1 ................................................................................................... 29 
2.2.1.1 Specific Aim 1 ................................................................................. 29 
2.2.1.2 Specific Aim 2 ................................................................................. 30 
2.2.2 Objective 2 ................................................................................................... 30 
2.2.2.1 Specific Aim 1 ................................................................................. 30 
2.2.2.2 Specific Aim 2 ................................................................................. 30 
2.3 Hypothesis............................................................................................................. 30 
 viii
CHAPTER 3 .................................................................................................................. 31 
3. Materials and Methods............................................................................................... 31 
3.1 Materials................................................................................................................ 31 
3.1.1 Chemicals..................................................................................................... 31 
3.1.2 Animals ........................................................................................................ 32 
3.2 Inhibition of Cytochrome P450 (CYP) 3A, 2B and 2C11 by the Flaxseed 
Plant Lignans Secoisolariciresinol Diglucoside and Secoisolariciresinol ............ 32 
3.2.1 Preparation of Hepatic Microsomes for Inhibition Experiments ................. 32 
3.2.2 Determination of Hepatic Microsomal Protein and Cytochrome 
P450 Content................................................................................................ 33 
3.2.3 Validation of a High Performance Liquid Chromatography 
Testosterone Metabolism Assay to Assess Changes in Enzyme 
Activity......................................................................................................... 34 
3.2.3.1 Determination of an Appropriate Testosterone High 
Performance Liquid Chromatography Method to Detect 
Changes in 6β-, 16α- and 2α-OH Testosterone Formation .............. 34 
3.2.3.2 Preparation of Stock Solutions of Testosterone and 
Metabolite Standards........................................................................ 35 
3.2.3.3 Testosterone High Performance Liquid Chromatography 
Assay Validation .............................................................................. 35 
3.2.4 Determination of Cytochrome P450 (CYP) 3A, 2B and 2C11 
Inhibition Mechanism by the Flaxseed Plant Lignans 
Secoisolariciresinol Diglucoside and Secoisolariciresinol........................... 36 
3.2.4.1 Time and Concentration Dependent Inhibition (Irreversible 
Inhibition) of CYP3A, CYP2B and CYP2C11 by the 
Flaxseed Plant Lignans Secoisolariciresinol Diglucoside 
and Secoisolariciresinol .................................................................. 37 
3.2.4.2 Substrate and Inhibitor Concentration Dependent Inhibition 
(Reversible Inhibition) of CYP3A, CYP2B and CYP2C11 
by Secoisolariciresinol ..................................................................... 38 
3.2.4.3 Statistical Analysis ........................................................................... 38 
3.3 Development of a Method to Assess Phase I and Phase II Enzyme 
Induction in Rat Primary Hepatocytes .................................................................. 39 
3.3.1 Development of Real-Time Reverse-Transcription-Polymerase 
Chain Reaction Assays to Assess Cytochrome P450 and Phase II 
Enzyme Induction in Rat Primary Hepatocytes ........................................... 39 
3.3.2 Control RNA Extraction and Quantitation for Optimization of 
Real-Time Reverse Transcription-Polymerase Chain Reaction 
Assays .......................................................................................................... 40 
3.3.2.1 Isolation of Total RNA from Control Male and Female 
Liver and Lung Tissue ..................................................................... 40 
3.3.2.2 Determination of Total RNA Purity and Yield ................................ 41 
3.3.3 Real-Time Reverse Transcription-Polymerase Chain Reaction 
Assessment of Primer Sets for Optimal Gene Amplification ...................... 41 
3.3.3.1 Selection of Appropriate Primers Based on Real-Time 
Reverse Transcription-Polymerase Chain Reaction 
Amplification ................................................................................... 41 
 ix
3.3.3.2 Determination of Primer Set Real-Time Reverse 
Transcription-Polymerase Chain Reaction Target Product 
Amplification by Agarose Gel Electrophoresis ............................... 43 
3.3.4 Determination of Optimal Primer Sets for Target Gene 
Amplification by Real-Time Reverse Transcription-Polymerase 
Chain Reaction............................................................................................. 43 
3.3.5 Isolation of Rat Primary Hepatocytes to use for Assessments of 
Cytochrome P450 and Phase II Enzyme Induction...................................... 44 
3.3.5.1 Procedures Involved in the Isolation and Culture of Rat 
Primary Hepatocytes ........................................................................ 44 
3.3.5.2 General Procedure Used for the Isolation of Rat Primary 
Hepatocytes ...................................................................................... 46 
3.3.5.3 Determination of Cell Viability and Yield of Rat Primary 
Hepatocytes ...................................................................................... 46 
3.3.5.4 Techniques for Plating and Culturing Rat Primary 
Hepatocytes ...................................................................................... 47 
3.3.5.5 Determination of Enzyme Induction in Cultured Rat 
Primary Hepatocytes ........................................................................ 47 
3.3.5.6 Harvesting of Rat Primary Hepatocytes and Extraction of 
RNA ................................................................................................. 48 
 
CHAPTER 4 .................................................................................................................. 50 
4. Results ........................................................................................................................ 50 
4.1 Inhibition of 6β-, 16α- and 2α-OH Testosterone Formation by 
Secoisolariciresinol and Secoisolariciresinol Diglucoside.................................... 50 
4.1.1 High Performance Liquid Chromatography Method Validation 
Parameters for Quantification of Testosterone Metabolites......................... 50 
4.1.2 Pre-incubation Time and Concentration Dependent (Irreversible) 
Inhibition of 6β-, 16α- and 2α-OH Testosterone Formation in 
Pooled Rat Hepatic Microsomes by Secoisolariciresinol and 
Secoisolariciresinol Diglucoside.................................................................. 55 
4.1.3 Substrate and Inhibitor Concentration Dependent Inhibition of 6β-, 
16α- or 2α-OH Testosterone Formation by Secoisolariciresinol ................. 58 
4.2 Determination of a Method to Assess Induction of Cytochrome P450 
and Phase II enzymes by Secoisolariciresinol Diglucoside and 
Secoisolariciresinol in Primary Rat Hepatocytes.................................................. 61 
4.2.1 Optimized Primer Sets for Target Gene Amplification using Real-
Time Reverse Transcription-Polymerase Chain Reaction ........................... 61 
4.2.2 Isolation and Culture of Rat Primary Hepatocytes: Method 
Development ................................................................................................ 64 
4.2.2.1 Hepatocyte Isolation Conditions ...................................................... 64 
4.2.2.1.1 Isolation of Rat Primary Hepatocytes ............................... 64 
4.2.2.1.2 Hepatocyte Dissociation.................................................... 64 
4.2.2.1.3 Viability and Cell Yield .................................................... 64 
4.2.2.2 Hepatocyte Plating and Culturing .................................................... 65 
4.2.2.3 Hepatocyte Harvesting and RNA Isolation...................................... 65 
4.2.2.3.1 Harvesting of Primary Rat Hepatocytes............................ 66 
 x
4.2.2.3.2 RNA Isolation from Primary Rat Hepatocytes ................. 66 
4.2.2.4 Verification of Hepatocyte Culture Conditions and 
Inducibility ....................................................................................... 66 
 
CHAPTER 5 .................................................................................................................. 68 
5. Discussion .................................................................................................................. 68 
5.1 Drug Interactions................................................................................................... 69 
5.2 Drug Interactions Caused by Secoisolariciresinol and 
Secoisolariciresinol Diglucoside........................................................................... 71 
5.3 Inhibition of Cytochrome P450 by Secoisolariciresinol and 
Secoisolariciresinol Diglucoside........................................................................... 73 
5.3.1 Effects of Secoisolariciresinol Diglucoside on Cytochrome P450 
Enzymes ....................................................................................................... 74 
5.3.2 Effects of Secoisolariciresinol on Cytochrome P450 Enzymes................... 74 
5.3.2.1 CYP3A Effects................................................................................. 74 
5.3.2.2 CYP2B and CYP2C11 Effects......................................................... 77 
5.4 Relevance of Inhibition Results ............................................................................ 78 
5.5 Development of a Rat Primary Hepatocyte Culture System................................. 81 
 
CHAPTER 6 .................................................................................................................. 85 
6. Conclusions and Perspectives .................................................................................... 85 
 
CHAPTER 7 .................................................................................................................. 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi
LIST OF TABLES 
Table               Page 
 
Table 1.1: Transcriptional mechanisms of induction for selected 
cytochrome P450 enzymes........................................................................... 13 
 
Table 1.2: The transcriptional co-induction of cytochrome P450 and phase 
II enzymes by transcription factors .............................................................. 15 
 
Table 1.3: Natural compounds found in food and natural health products 
that have been shown to induce cytochrome P450, uridine 
diphosphate – glucuronosyltransferase or glutathione-S-
transferase isoforms ..................................................................................... 16 
 
Table 1.4: Common compounds in foods and natural health products that 
inhibit cytochrome P450 and uridine diphosphate-
glucuronosyltransferase isoforms ................................................................ 19 
 
Table 1.5: Relationship between induction response for enzyme activity, 
mRNA and protein levels for cytochrome P450 following 
exposure to classical inducers in rat liver tissue .......................................... 25 
 
Table 3.1: Initial and final concentrations of dexamethasone, 
phenobarbital, tert-butylhydroquinone and β-naphthoflavone 
used to induce cytochrome P450 and phase II enzymes in 
primary rat hepatocytes ................................................................................ 48 
 
Table 4.1: Testosterone high performance liquid chromatography assay 
slope, y-intercept and coefficient of determination for 6β-OH 
testosterone for four separate standard curves conducted in 
triplicate ....................................................................................................... 52 
 
Table 4.2: Testosterone high performance liquid chromatography assay 
slope, y-intercept and coefficient of determination for 16α-OH 
testosterone for four separate standard curves conducted in 
triplicate ....................................................................................................... 52 
  
Table 4.3: Testosterone high performance liquid chromatography assay 
slope, y-intercept and coefficient of determination for 2α -OH 
testosterone for four separate standard curves conducted in 
triplicate ....................................................................................................... 53 
 
Table 4.4: Inter-day (range over 3 days), and intra-day (mean ± S.D.) 
accuracy and precision values of 6β-OH testosterone following 
high performance liquid chromatography-ultraviolet detection 
in rat hepatic microsomes ............................................................................ 54 
 xii
Table 4.5: Inter-day (range over 3 days), and intra-day (mean ± S.D.) 
accuracy and precision values of 16α -OH testosterone 
following high performance liquid chromatography-ultraviolet 
detection in rat hepatic microsomes............................................................. 54 
 
Table 4.6: Inter-day (range over 3 days), and intra-day (mean ± S.D.) 
accuracy and precision values of 2α -OH testosterone 
following high performance liquid chromatography-ultraviolet 
detection in rat hepatic microsomes............................................................. 55 
 
Table 4.7: The percent of control activity for the formation of 6β-, 16α- 
and 2α-OH testosterone in pooled (n=4) rat liver microsomes 
by 1600 μM Secosiolariciresinol at the KM, 2KM and ~VMax 
concentration of testosterone........................................................................ 60 
 
Table 4.8: Primer sequence, accession number, control tissue, product 
size, annealing temperature and efficiency (E) for optimized 
primer sets for target genes on the Cepheid SmartCycler real-
time reverse transcription-polymerase chain reaction system 
using QIAGEN SYBR green real-time reverse transcription-
polymerase chain reaction kits ..................................................................... 63 
 
Table 4.9: The number of wells per plate, diameter, growth area, media 
volume and number of cells per well for different plates used in 
cell culture.................................................................................................... 65 
 
Table 4.10: Positive control-fold induction of target genes based on real-
time reverse transcription-polymerase chain reaction data from 
single plate experiments............................................................................... 67 
 
Table 5.1: Prediction of in vivo inhibition based on in vitro reversible 
inhibition constants ...................................................................................... 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii
LIST OF FIGURES 
Figure               Page 
 
Figure 1.1: Conversion of secoisolariciresinol diglucoside (SDG) to 
secoisolariciresinol (SECO) by β-glucuronidase and β-
glucosidase and subsequent conversion to the mammalian 
lignans enterolactone and enterodiol by colonic bacteria ............................ 6 
 
Figure 1.2: Chemical structure of cytochrome P450 inducers; A) 
simvastatin (top) or cytochrome P450 inhibitors, B) (-) 
dihydroclusin (a methylenedioxyphenyl lignan), C) sesamin (a 
sesame lignan), D) Bisphenol A, E) silybin and F) 
nordihydroguaiaretic acid (middle) and Phase II inducer and 
CYP inhibitor, G) schisandrin (a lignan from Fructus 
schizandrae) (bottom) .................................................................................. 22 
 
Figure 4.1: Representative high performance liquid chromatography 
chromatograms for the validation of 6β-, 16α- and 2α-OH 
testosterone, A) blank rat hepatic microsomes; B) quality 
control sample with internal standards, acetaminophen (3.7 
min) and dimethylphenylacetone (13.6 min); C) microsomal 
incubation with testosterone (50 μM); and D) inset showing 
metabolite peaks........................................................................................... 51 
 
Figure 4.2: The effect of increasing Secoisolariciresinol (SECO) 
concentration and preincubation time on the formation of a) 
6β-, b) 16α- and c) 2α-OH testosterone, as determined by high 
performance liquid chromatography, in pooled male rat hepatic 
microsomes (n=4) following incubation with testosterone for 
15 minutes.  Each point represents the mean of 3 replicates ± 
the standard deviation ................................................................................. 56 
 
Figure 4.3: The effect of increasing Secoisolariciresinol Diglucoside 
(SDG) concentration and preincubation time on the formation 
of a) 6β-, b) 16α- and c) 2α-OH testosterone, as determined by 
high performance liquid chromatography, in pooled male rat 
hepatic microsomes (n=4) following incubation with 
testosterone for 15 minutes.  Each point is the mean of 3 
replicates ± the standard deviation............................................................... 57 
 
Figure 4.4: Secoisolariciresinol (SECO) concentration dependent 
inhibition of 6β-OH testosterone formation with 50, 100 or 250 
μM testosterone in a 15 minute incubation with pooled (n=4) 
male, rat liver microsomes.  Each point represents the mean of 
3 replicates ± the standard deviation............................................................ 58 
 
 xiv
Figure 4.5: Secoisolariciresinol (SECO) concentration dependent 
inhibition of 16α-OH testosterone formation with 50, 100 or 
250 μM testosterone in a 15 minute incubation with pooled 
(n=4) male, rat liver microsomes.  Each point represents the 
mean of 3 replicates ± the standard deviation.............................................. 59 
 
Figure 4.6: Secoisolariciresinol (SECO) concentration dependent 
inhibition of 2α-OH testosterone formation with 50, 100 or 250 
μM testosterone in a 15 minute incubation with pooled (n=4) 
male, rat liver microsomes.  Each point represents the mean of 
3 replicates ± the standard deviation............................................................ 60 
 
Figure 4.7: Lineweaver-Burke plot of the inverse relationship between 
substrate (testosterone) concentration and enzyme velocity at 
varying concentrations of Secosiolariciresinol (SECO) for 6β-
OH testosterone formation.  Each point is the mean of 3 
replicates ...................................................................................................... 61 
 
Figure 4.8: Separation of cytochrome P450 (CYP) 1A1, uridine 
diphosphate-glucuronosyltransferase (UGT) 2B12, 2B3 and 
2B1 real-time reverse transcription-polymerase chain reaction 
amplification products by agarose gel electrophoresis.  The 
molecular weight marker (shown on the right and left) has band 
sizes of 489, 404, 353, 242, 190, 147 and 110 base pairs.  Each 
sample was run in duplicate with a non-template control 
sample (containing primers with no RNA) on the left................................. 62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv
LIST OF ABBREVIATIONS 
 
ACN – Acetonitrile 
AhR – Aryl Hydrocarbon Receptor 
AhRE – Aryl Hydrocarbon Responsive Element 
ARE – Antioxidant Response Element 
ARNT – Aryl Hydrocarbon Receptor Nuclear Translocation Protein 
CAR – Constitutive Androstane Receptor 
E – Amplification Efficiency 
tBHQ – tert-Butylhydroquinone 
CVD – Cardiovascular Disease 
CYP – Cytochrome P450 
DEX - Dexamethasone 
DMPA – Dimethylphenylacetone 
DMSO – Dimethylsulfoxide 
END – Enterodiol 
ENL – Enterolactone 
FBS – Fetal Bovine Serum 
FDA – Food and Drug Administration 
GR – Glucocorticoid Receptor 
GSH - Glutathione 
GST – Glutatione-S-Transferase 
HPLC – High Performance Liquid Chromatography 
IC50 – Inhibitor concentration causing 50% inhibition 
 xvi
Keap-1 – Kelch-like ECH Associated Protein 1 
KHB – Krebs-Henseleit Buffer 
LOQ – Limit of Quantitation 
M-M – Michaelis-Menten (kinetics) 
NADPH - Nicotinamide Adenine Dinucleotide Phosphate 
NCBI – National Center for Biotechnology Information 
βNF – β-Naphthoflavone 
NFκB – Nuclear Factor κB 
NHP – Natural Health Product 
NHPD – Natural Health Products Directorate 
NQO1 - NAD(P)H Dehydrogenase, Quinone 1 
Nrf2 – Nuclear Factor Erythroid Derived 2 
NTC – Non-template Control 
PB - Phenobarbital 
PBRE – Phenobarbital Response Element 
PD - Pharmacodynamics 
PK – Pharmacokinetics 
PPARα – Peroxisome Proliferator Activated Receptor α 
PXR – Pregnane X Receptor 
PXRRE – PXR Response Element 
QC – Quality Control 
QRT-PCR – Quantitative RT-PCR 
r2 – Coefficient of Determination 
RSD – Relative Standard Deviation 
 xvii
RT-PCR – Reverse Transcription-Polymerase Chain Reaction 
RXR – Retinoid X Receptor 
S.D. – Standard Deviation 
SD – Sprague-Dawley (rats) 
SDG – Secoisolariciresinol Diglucoside 
SECO – Secoisolariciresinol 
SULT – Sulphotransferase 
SXR – Steroid/Xenobiotic Receptor 
TFA – Triflouroacetic Acid 
UGT – Uridine Diphosphate-Glucuronosyltransferase 
v – Enzyme Velocity 
VDR – Vitamin D Receptor 
XRE – Xenobiotic Response Element 
 
 
 
 
 
 
 
 1
CHAPTER 1 
1. Literature Review 
1.1 Introduction 
Flaxseed, a major crop in Saskatchewan, has many purported health benefits, 
particularly in regards to cardiovascular disease, cancer and type II diabetes.  The plant 
lignan, secoisolariciresinol diglucoside (SDG), is found in high concentrations in 
flaxseed.  Studies indicate that the lignan components of flax, SDG and its aglycone 
secoisolariciresinol (SECO), mediate many of the beneficial effects in disease treatment 
and prevention.  Thus, flax is being promoted as a beneficial natural product for 
consumers. 
The possibility of drug interactions is a major concern with natural health 
products.  Several serious consequences have arisen from natural products taken 
concomitantly with pharmaceutical agents.  These drug interactions often arise from 
induction or inhibition of cytochrome P450 or phase II enzymes.  The lignans are likely 
candidates for drug metabolizing enzyme interactions for several reasons: (i) they are 
capable of oxidative and phase II metabolism1-4, (ii) lignans show time and dose 
dependent pharmacokinetics3,5,6 (iii) structurally similar compounds are inducers and/or 
inhibitors7,8, (iv) lignans likely undergo enterohepatic circulation9 and (v) SECO can 
induce human PXR in vitro10 and flaxseed induces gamma-glutamyltranspeptidase in 
vivo11. 
 Given the high consumption of flax, SDG and SECO need to be examined for 
potential metabolic interactions.  Investigation of potential drug interactions via 
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induction and inhibition of drug metabolizing enzymes with plant lignans is needed to 
ensure consumer safety.   
 
1.2 Natural Health Products 
1.2.1 Natural Health Products – An Introduction 
Natural Health Products (NHPs) are defined by the Natural Health Products 
Directorate (NHPD) under the Food and Drugs Act as substances which are 
“manufactured, sold or represented for use in: (i) the diagnosis, treatment, mitigation or 
prevention of a disease, disorder, or abnormal physical state or its symptoms in humans; 
(ii) restoring or correcting organic functions in humans; or (iii) modifying organic 
functions in humans such as modifying those functions in a manner that maintains or 
promotes health”12.  Natural health products can be purified components taken in dosage 
form, or can be components of fortified foods with health claims.  Usually, the levels of 
the active components achieved following ingestion of an NHP are greater than those 
that could be obtained from the original source alone. 
 
1.2.2 Natural Health Products and Consumer Use/Attitudes in Canada 
The NHPD created regulations governing NHP usage in Canada in 2001.  These 
regulations are intended to protect Canadian consumers by providing “NHPs that are 
safe, effective and of high quality, while respecting freedom of choice and philosophical 
and cultural diversity”12.   
Surveys indicate that more than half of Canadians already regularly use an 
NHP13 and that 71% of Canadians have used an NHP at some time13.  Furthermore, 52% 
of Canadians think a natural product is safe because it is made from natural ingredients, 
and 37% of the public feels a product is safe if it is for sale in Canada13.  The need for 
 3
determining product safety is evident if it is to be sold without a prescription, since 
many Canadians do not give NHPs the same scrutiny as “pharmaceutical agents”. 
Classic examples of approved NHPs include St. John’s Wort, Glucosamine, and 
Goldenseal14.  Various formulations of flaxseed oil and capsules are currently on the 
market in Canada.  There is also a compound known as BioWisdom enteroflax14.  The 
components of the compounds are not released to the public.  Other products, such as 
Flora High Lignan Flax Oil, are available for purchase and not approved by Health 
Canada14.  
 
1.3 Flaxseed  
1.3.1 Components and Growth 
1.3.1.1 Flaxseed Industry 
Flax production has a rich global history, beginning around 3000 B.C.E.  Since 
its introduction flax has been used as both a food source and in the manufacturing of 
certain products, such as linoleum15.  The most common commercially grown flaxseed, 
one of the five major crops grown in Canada, is the oilseed strain L. usitatissimum. 
Additionally, Canada is the largest producer and exporter of flax gobally15 and almost 
90% of Canadian flax is exported around the world15.  The economic importance of 
flaxseed is currently unrelated to its role as an NHP.  The use of flaxseed and/or its 
lignan components as a treatment or preventative agent in disease would boost the 
economic value of this crop in Canada. 
 
1.3.1.2 Flaxseed Components 
Flaxseed is an oil seed whose seed mass is 32-45% oil with α-linolenic acid (an 
omega-3 fatty acid) comprising approximately 51-55% of the oil16.  Flaxseed also 
contains a high level of dietary fibre. Both α-linolenic acid and fibre have their own 
associated health benefits.   
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The SDG content of whole flaxseed is between 6.1 – 13.3 mg/g of whole 
flaxseed17.  Flaxseed contains greater than 100 times the levels of SDG as other food 
sources, such as bramble, soy beans, garlic and tea18.   Secoisolariciresinol diglucoside 
consists of one SECO molecule with two attached glucose molecules19 and exists in the 
plants as a hydroxymethylglutaryl (HMG) polymer20.  Lower levels of other plant 
lignans, such as matairesinol, isolariciresinol, pinoresinol21, and demethoxy-
secoisolariciresinol22 are also found in flaxseed.  These lignans are the likely source of 
many beneficial effects associated with flaxseed use.   
  Importantly, the majority of the plant lignans are located in the aleuronic layer 
of the seed coat, thus milled flaxseed often has a low lignan content18, and ingestion may 
not provide all the benefits associated with flaxseed use.   
 
1.3.2 Health Benefits Related to the Flaxseed Lignans 
Flaxseed lignans are beneficial in the treatment and/or prevention of 
cardiovascular disease (CVD), cancer and diabetes.  Epidemiological studies have 
recognized the advantages of lignan use in CVD9,18 and various types of cancer9,18,23-25 in 
humans.  Animal studies and in vitro models have shown benefits in CVD, cancer and 
diabetes9,18,26-30.  The mechanism of action may relate to the ability of lignans to act as 
antioxidants31,32 or interact with the estrogen receptor18.  The beneficial effects may 
result from one single mechanism, or be the result of a combination of effects.  The fate 
of flaxseed, both in terms of pharmacokinetics (PK) and pharmacodynamics (PD), is 
required to exploit these benefits in the human population.  Currently, little information 
is available on the safety of purified lignan ingestion, especially with concomitant use of 
other NHPs and drugs. 
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1.3.3 Status of Flaxseed as a Natural Health Product 
The recommended daily dose of flaxseed for the beneficial fatty acids or as a 
bulk-forming laxative is 1-10g, 3 times a day33. Since clinical trial data is largely absent, 
these dosage recommendations do not necessarily reflect possible benefits and risks 
associated with consumption of plant lignans.  According to the Flax Council of Canada, 
individuals are recommended to avoid consuming flax or flax products without first 
consulting a physician34.  The NHPD monograph of flaxseed advises that the public 
consult a health care professional if they are taking medications which decrease blood 
clotting or have a bleeding disorder prior to incorporating flaxseed into their diets33.  It is 
also recommended that a person not ingest flaxseed within two hours of another 
medication33.  These recommendations are safeguards to prevent the possibility of drug 
interactions.  However, these guidelines may not be sufficient for the use of purified 
lignans and no monograph is currently available on either SECO or SDG.  It is critical to 
evaluate the PK of SDG and SECO, to understand the possible impacts on drug 
metabolizing enzymes. 
 
1.3.4 Plant and Mammalian Lignan Pharmacokinetics 
The PK of SDG are complex which increases the risk of drug interactions.  The 
subsequent sections will outline the absorption, metabolism, distribution and excretion 
of the lignans in rats following ingestion.  Figure 1 is a simplified schematic of SDG 
breakdown in mammals.  This section also notes the similarities between human and rat 
PK. 
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Figure 1.1: Conversion of secoisolariciresinol diglucoside (SDG) to secoisolariciresinol 
(SECO) by β-glucuronidase and β-glucosidase and subsequent conversion to the 
mammalian lignans enterolactone and enterodiol by colonic bacteria 
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1.3.4.1 Absorption and Intestinal Metabolism in Rats  
Initially, the polymerized SDG is broken down into individual molecules and the 
glucose groups are cleaved off in the intestine by β-glucuronidase and β-glucosidase35.  
Secoisolariciresinol is absorbed directly36 and/or continues through the gastrointestinal 
tract to the colon, where it is converted into the mammalian lignans, enterolactone 
(ENL) and enterodiol (END), by bacterial demethylation and dehydroxylation9.  
Oxidation by facultative bacteria can produce ENL from END9.  Consequently, ENL is 
the more abundant mammalian lignan following SDG ingestion37.  The mammalian 
lignans are absorbed from the colon and can enter the systemic circulation.  
It is difficult to determine absorbed levels of lignans due to a variety of factors 
related to the metabolism and excretion of SECO and SDG. 
 
1.3.4.2 Oxidative and Phase II Metabolism in Rats  
 Oxidative phase I metabolism does not play a major role in lignan metabolism36.  
However, rat liver microsomes produce hydroxylated metabolites following incubation 
with SECO38.  Small amounts of monodemethylated matairesinol, 4,4’-dihydroxy-ENL 
and 7-oxy-ENL were identified in rat urine following exposure to SECO4, indicative of 
lignan oxidative metabolism in vivo.  A change in the lignan metabonome is observed 
when specific CYP enzymes are induced39, providing further evidence that CYP 
enzymes contribute in vivo to lignan metabolism in the rat.    
Phase II conjugation reactions play a major role in the metabolism of plant and 
mammalian lignans1-3.  The major phase II metabolites of the mammalian lignans are 
mono-glucuronides and sulphides2.  These metabolites can be excreted into the bile or 
distributed to other tissues.      
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1.3.4.3 Distribution in Rats 
Following dietary flaxseed consumption, one or more of the lignans distribute to 
the liver, kidney, uterus and adipose tissue5.  However, less than 1% of total lignan 
administered was detected in blood; the majority of the dose did not enter systemic 
circulation5,36 or the tissues5. Concentration and time dependent distribution differences 
have been observed following SDG oral administration, particularly with time of 
systemic peak concentrations and the extent of distribution to the liver, adipose tissue, 
colon and ovaries5,6.   
   
1.3.4.4 Excretion in Rats 
Biliary and fecal excretion are the principal routes of lignan excretion.  Only 
25% of an administered dose of SECO will be eliminated in the urine within 24 hours36.  
The significant amount of lignan excretion into the feces suggests extensive 
enterohepatic recirculation of the plant and mammalian lignans.   The major urinary 
compounds following SDG administration are END, SECO and ENL36.  Lignan 
excretion may3,6 or may not36 be altered in chronic versus acute exposure. 
 
1.3.4.5 Enterohepatic Circulation 
The glucuronidated mammalian lignans can be excreted in the bile, where β-
glucuronidase in the gastrointestinal tract can cleave off the glucuronide group, resulting 
in END and ENL re-absorption9. Enterohepatic recirculation enhances liver and 
intestinal exposure to the lignans.  
Limited systemic levels of the plant lignans5,36 indicate extensive first pass 
metabolism following oral ingestion. Since the plant lignans are extensively 
glucuronidated, they may also undergo enterohepatic circulation, leading to high hepatic 
levels without high plasma concentrations.  This argument is strengthened by evidence 
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suggesting that flaxseed ingestion itself increases β-glucuronidase activity, thereby 
enhancing enterohepatic recirculation24.  The active site concentration in the intestine 
and liver of SECO, SDG and the mammalian lignans, will be much greater than that 
predicted from systemic levels.   It is difficult to predict these levels given the excretion 
in the bile, interconversion within the intestine and liver and enterohepatic circulation.  
The bioavailability of the lignans remains elusive.      
 
1.3.4.6 Lignan Pharmacokinetics in Humans 
 The PK of plant lignans in rats is similar to results in humans.  The major 
similarities in plant and mammalian lignan PK include similar oxidative capabilities38,39, 
distribution5,9,36 and excretion profiles3,6,36.  Dose and time dependent PK are observed 
in humans and rats.  The key difference is bioavailability, where species differences 
arise as a result of differences in microflora and exposure to environmental factors18. 
The PK data available on lignans support the use of the rat as an animal model 
and the hypothesis of enzyme interactions since the lignans are a substrate for oxidative 
and phase II metabolism, likely undergoes enterohepatic recirculation and PK 
parameters show time and concentration dependent changes. 
Human males and females show differences in mammalian lignan time of 
maximum plasma concentration and mean residence time37.  These differences may 
result from altered absorption or phase II conjugation.   
 
1.3.5 Toxicity  
Metabolic studies reported no overt signs of toxicity following acute and sub 
chronic flaxseed and SDG dosing. Chronic oral dosing of SDG to pregnant and lactating 
rats resulted in no effects on growth, behavioural, reproductive and developmental 
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indices of offspring11,40-42.  Furthermore, lignans do not cause DNA damage in vitro43,44.  
However, flaxseed ingestion causes the induction of hepatic gamma-
glutamyltranspeptidase activity in both male and female rats11.  No studies to date have 
examined possible toxicity resulting from drug metabolizing enzyme induction or 
inhibition.   
 
1.4 Drug Metabolizing Enzymes 
1.4.1 Cytochrome P450 and Phase II Enzymes 
Drug metabolizing enzymes are generally classified as phase I, such as 
cytochrome P450 (CYP), or phase II, including uridine diphosphate (UDP) -
glucuronosyltransferase (UGT) and glutathione-S-transferase (GST).  These enzymes 
are responsible for the systemic removal of numerous endogenous and exogenous 
compounds, including the majority of pharmaceuticals and NHPs.   
 
1.4.1.1 Cytochrome P450 
The CYP enzymes are part of a heme-containing family responsible for the 
oxidative metabolism of both endogenous and exogenous compounds. The different 
CYP isoforms have broad and overlapping substrate specificity45.  The highest levels of 
CYPs are located in zone 3 of the hepatic acinus45.  The majority of ingested compounds 
enter the liver prior to entering the systemic circulation45 and may undergo significant 
first-pass metabolism.  Furthermore, CYP expression in the liver contributes a 
significant fraction to the overall metabolism of compounds via pre-systemic or systemic 
clearance mechanisms. 
 
1.4.1.2 Uridine Diphosphate-Glucuronosyltransferase 
Uridine diphosphate-glucuronosyltransferase is a phase II enzyme family 
responsible for the detoxification of endogenous and exogenous compounds, including 
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hydroxy-polychlorinated biphenyls46 and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK)47.  The UGT enzyme group can be divided into two major families, 
UGT1A and 2B.  Isoforms from the same family have overlapping substrate 
selectivities, meaning several isoforms can conjugate the same substrate48. 
In the rat, the UGT1A family primarily conjugates bilirubin and phenols49.  This 
family is produced through alternative splicing to produce different isoforms with 
identical amino acid sequences except for the N-terminus49.  They also have different 
promoters49.    UGT1A2, 3, 6 and 7 have significantly higher levels in the intestine than 
the liver50.  UGT1A5 and 8 have no intestinal expression, and are mainly found in the 
liver, with the latter also showing high expression levels in the kidney.  In the rat, 
UGT1A1 has the most diffuse distribution of all the UGTs, and is present in most 
systems, including the cerebellum and cortex50.  Only UGT1A5 and 8 show gender 
discrepancies, with approximately 2-fold higher concentrations in the female50.     
The UGT2B family results from separate gene products and also have different 
promoters.  This family primarily conjugates steroids49.  The UGT2B family is 
predominantly found in the liver. In the rat, UGT2B8 has low levels of liver mRNA, and 
its concentration is highest in the intestine50. UGT2B12 is fairly ubiquitous, with highest 
levels detected in the liver and kidney.  These enzymes show gender discrepancies, with 
most female rats showing greater than 2-fold higher levels of the isoform50.  UGT2B6 is 
the only member of this family where males show higher levels than females.  These 
gender differences are likely the result of differences in steroid profiles between male 
and female rats50.  The role of the UGT2B family in steroid conjugation makes it an 
ideal candidate for induction or inhibition by the lignans, which are structurally similar 
to endogenous steroids. 
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1.4.1.3 Glutathione-S-Transferase 
Glutathione-S-transferase is one of the key enzymes for detoxification of 
environmental contaminants, carcinogens and endogenous oxidative stress metabolites51.   
The GST enzymes are required for the synthesis of leukotrienes and testosterone51.  As a 
phase II enzyme, GST catalyzes the addition of glutathione (GSH) to a substrate52.         
The GST enzymes are cytosolic, membrane-bound or mitochondrial51.  The five 
major human cytosolic GST enzymes, important in detoxification reactions, are 
classified as alpha (A), mu (M), pi (P), theta (T) and sigma (S)53.  Expression levels vary 
with species, tissue location, age and gender53, with highest levels in the liver52.  In 
general, the Mu and Alpha class of enzymes have highest levels in the liver, whereas 
GSTP has higher levels in most other tissues52.    Polymorphisms are notable in the 
human population, and certain deficiencies, such as GSTM1, can lead to increased 
susceptibility to cancer52.  The ability of drug metabolizing enzymes to reliably detoxify 
foreign compounds and maintain internal homeostasis depends on its inducibility.  It is 
likely an adaptive mechanism in response to chemical and endogenous stress53.  An 
understanding of the mechanisms by which these enzymes can be induced is critical to 
assessing lignan potential for enzyme upregulation.     
 
1.4.2 Induction of Drug Metabolizing Enzymes 
1.4.2.1 Mechanisms of Induction 
Enzyme induction ultimately can cause increased enzyme activity.  It can occur 
via transcriptional, translational or post-translational mechanisms54.  Most enzymes are 
induced via transcription but protein stabilization45 and decreased protein degradation55 
also occur.  Transcriptional upregulation of enzyme expression is controlled by a group 
of promiscuous transcription factors and DNA response elements that have broad and 
overlapping effects between enzyme families and isoforms.  Transcriptional induction 
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requires an appropriate ligand-binding domain on the transcription factor to cause 
enzyme upregulation.     
 
1.4.2.2 Cytochrome P450 
The CYP family of drug metabolizing enzymes have a variety of active 
transcription factors.  Table 1.1 outlines only some of the identified pathways of 
transcriptional induction.  Induction mechanisms are complex and undergo significant 
cross-talk.  Exceptions to these general induction pathways have been well documented.   
 
Table 1.1: Transcriptional mechanisms of induction for selected cytochrome P450 
enzymes45,56,57  
Cytochrome P450 
Isoform 
Transcription 
Factor 
Dimerization 
Partner 
Receptor 
family 
1A AhR ARNT AhR 
2B, 3A & 2C CAR RXR Nuclear 
3A, 2B6 & 2C PXR RXR Nuclear 
4A PPARα RXR Nuclear 
2B6, 3A4 & 2C9 VDR RXR Steroid 
3A4 GR None Steroid 
3A4 SXR None Steroid 
AhR = aryl hydrocarbon receptor, ARNT = AhR nuclear translocation protein, CAR = constitutive 
androstane receptor, PXR = pregnane X receptor, PPARα = peroxisome proliferator activated receptor α, 
RXR = retinoid X receptor, GR = glucocorticoid receptor, SXR = steroid/xenobiotic receptor 
 
 
1.4.2.3 Uridine Diphosphate-Glucuronosyltransferase 
Uridine diphosphate-glucuronosyltransferase isoforms have an anti-oxidant 
response element (ARE), xenobiotic response element (XRE), aryl hydrocarbon 
responsive element (AhRE) or nuclear factor-kappa B (NFκB) site in the 5’ regulatory 
region of the gene58.  Some isoforms have multiple promoter sites, such as UGT1A659.   
Induction of UGT can occur via nuclear factor erythroid-derived 2 (Nrf2) without direct 
binding to the promoter region.  The transcription factor Nrf2 is bound to Kelch-like 
ECH-associated protein 1 (Keap-1) in the cell and can be induced by multiple pathways 
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via phosphorylation.  Inducers can cause increased mRNA by cleaving the Nrf2-Keap1 
complex and releasing Nrf2 to bind the ARE58. 
 
1.4.2.4 Glutathione-S-Transferase 
Glutathione-S-transferase enzymes have an ARE, XRE and/or Nrf2 response 
element in the promoter region and can be induced by a variety of compounds.  Classical 
GST inducers operate via the Nrf2 pathway60 whereas GSTA1 and GSTM contain an 
ARE domain in the promoter region58.  The ARE found with cytosolic GST genes is 
readily induced by electrophiles51. 
 
1.4.2.5 Induction Cross-Over Between Drug Metabolizing Enzyme Families 
Induction of multiple isoforms from multiple families by a single compound is 
not uncommon.  This is because some CYP, UGT and GST isoforms have the same 
response element in the promoter region, such as the ARE58,61,62.  Multiple isoform 
induction is also caused by similarities in the ligand-binding domain of different 
transcription factors.  Phenobarbital (PB) can induce phase I (CYP2B1 and 3A1) and 
phase II (GSTA1, A2, A3 and M1, UGT2B1) enzymes in rats, although phase I 
induction is mediated by the CAR-RXR complex binding to the PB response element 
(PBRE) and none of the phase II enzymes have an identified PBRE in the promoter 
region58.  Table 1.2 lists the overlap in gene induction between phase I and phase II 
enzymes.     
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Table 1.2: The transcriptional co-induction of cytochrome P450 and phase II enzymes 
by transcription factors 58,63   
Transcription 
Factor 
Response 
Element 
Cytochrome 
P450 
Phase II 
AhR-ARNT XRE 1A1/1, 1B1 UGT, GST, Aldehyde 
dehydrogenase, NQO1 
PXR-RXR PXRRE 3A4, 2B6, 2C9, 
7A1 
UGT1A 
CAR-RXR PBRE 2B6, 2C9, 3A4 UGT1A1, SULT 
AhR = aryl hydrocarbon receptor, ARNT = AhR nuclear translocation protein, XRE = xenobiotic response 
element, CAR = constitutive adrostane receptor, RXR = retinoid X receptor, PBRE = phenobarbital 
response element, PXR = pregnane X receptor, PXRRE = PXR response element 
 
Currently, there are no predictive structure-activity models to determine if a 
compound will induce drug metabolizing enzymes.  General guidelines have been 
developed for some classes of compounds.  For example, hydroxylated flavonoids 
generally inhibit activity, whereas non-hydroxylated flavonoids generally induce64.  
Natural and chemical phase II inducers belong to at least eight different chemical 
families but they share three general properties: most are electrophiles, can react with 
sulphydryl groups and most are substrates for GST65.  These differences highlight the 
need to test the lignans for enzyme induction directly, because prediction based on 
chemical structure is not accurate enough to ensure the absence or presence of drug 
metabolizing enzyme levels.   
 
1.4.2.6 Natural Products as Inducers 
The mandate of the NHPD is to increase safety consumer safety, because 
induction of CYP, UGT and GST by natural products can lead to drug interactions in 
vivo.  Numerous NHPs, such as those listed in Table 1.3, can cause drug interactions by 
inducing one or more enzymes.    The most classic example involves St. John’s Wort, 
which induces CYP3A4 and 2C9 in humans66.   
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Table 1.3: Natural compounds found in food and natural health products that have been 
shown to induce cytochrome P450, uridine diphosphate – glucuronosyltransferase or 
glutathione-S-transferase isoforms 10,64,67-72 
Compound Family Isoform Induced 
Bergamottin Furocoumarins CYP1A1 
Resveratrol Polyphenols 
CYP2D9 
CYP2C29 
UGT1A1, 1A6, 1A7 
1-alpha 25-dihydroxy 
vitamin D3 Cholesterol PXR* 
Tangeritin Flavone Flavonoids CYP1A1/2, CYP2B1/2 
Green Tea Extract Complex CYP1A1 
Flavanone Flavonone Flavonoids 
CYP2B 
UGT 
Indigo  CYP1A1/2 
Chrysin, luteolin and 
apigenin Flavones 
CYP1A1/2 
CYP2B1/2 
CYP2E1 
CYP3A 
Seleno-cysteine 
Conjugates  GST 
*This study was a transfection assay using PXR and did not examine the induction of specific enzymes 
PXR = pregnane X receptor, UGT = uridine diphosphate-glucuronosyltransferase, CYP = cytochrome 
P450, GST = glutathione-s-transferase 
 
 
 There are numerous examples of natural products that do not induce CYP, UGT 
or GST.  These compounds include: protocatechuic and tannic acids73, soy isoflavones74, 
Panax ginseng and Panax quinquefolius extracts75.  Tangeretin and quercetin do not 
induce UGT isoforms64.  Consequently, it is important to examine the potential of NHPs, 
including SECO and SDG, to cause increased enzyme activity.   Due to species 
differences in the ligand binding domain of the transcription factors, induction by natural 
compounds may not be conserved across species76.   
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1.4.3 Inhibition of Drug Metabolizing Enzymes 
1.4.3.1 Mechanisms of Enzyme Inhibition 
Enzyme inhibition, the decrease in enzyme activity by other compounds, is a 
potential cause of drug interactions.  Secoisolariciresinol and SDG must be assessed for 
the presence and degree of inhibition.  The most recognized drug interaction arising 
from enzyme inhibition caused by an NHP is grapefruit juice and CYP3A4.  
Bergamottin and 6’,7’-dihydroxybergamottin inhibit CYP3A4.  The primary site of 
action is the intestine and has caused serious complications in patients on drugs that are 
substrates for CYP3A477.  Flaxseed lignans could cause drug interactions by inhibiting 
metabolic enzymes in the liver or intestine. 
There are two main types of inhibition: irreversible (i.e. mechanism-based) and 
reversible (i.e. competitive, uncompetitive and non-competitive).  Irreversible inhibitors 
interact through the catalytic cycle of the enzyme and cause permanent inactivation of 
the enzyme usually by covalent binding78.  Competitive inhibitors, the most common 
type of CYP enzyme reversible inhibitor79, compete with other substrates for the active 
site of the enzyme78.  Non-competitive inhibitors bind to a site of the enzyme separate 
from the active site, consequently, the inhibitor can bind the enzyme alone or the 
enzyme-substrate complex80.  In contrast, uncompetitive inhibitors can only bind the 
enzyme-substrate complex80.        
Cytochrome P450 reversible inhibition is often based on the assumption of 
Michaelis-Menten (M-M) kinetics.  This model assumes there is one active site on the 
enzyme, and that enzyme activity is saturable, resulting in a hyperbolic relationship 
between substrate and product80.  The KM is the concentration of substrate in which half 
the enzyme binding sites are occupied.  The VMax is the maximum velocity of product 
formation80.  With M-M kinetics, competitive inhibitors decrease the enzyme KM but 
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VMax remains unchanged80, non-competitive inhibitors decrease VMax but do not effect 
KM, and uncompetitive inhibitors decrease both KM and VMax80.   
However, many enzymes, particularly CYP3A, do not follow M-M kinetics, 
resulting in activation, partial inhibition and differential kinetics80.  In the case of 
CYP3A4, the large active site can accommodate more than one molecule 
simultaneously80 and can undergo activation through allosteric interactions80.  Activation 
of CYP3A4 has been observed with clinical drugs80.   
In general, the potency of an inhibitor towards an enzyme is represented by its 
IC50.  This is the inhibitor concentration that causes 50% inhibition of the enzyme.  For 
reversible inhibitors, Ki, the inhibitor constant, is used to indicate inhibitor potency80.  
All types of inhibition can result in drug interactions, although irreversible inhibitors are 
often the most potent, since these compounds inactivate the protein permanently79.  As a 
general rule, the more potent the inhibitor and more narrow the therapeutic window of 
the coadministered drug, the greater the potential for drug interactions79. 
 
1.4.3.2 Cytochrome P450 
Cytochrome P450 inhibition by natural compounds is well known and can be 
complex.  Inhibition can occur following metabolism by an isoform to cause irreversible 
inhibition81.  Natural compounds can also cause decreased total enzyme activity via 
transcriptional mechanisms.  Finally, some compounds have the ability to both induce 
and inhibit CYP isoforms, depending on the concentration at the active site70.   
 
1.4.3.3 Uridine Diphosphate-Glucuronosyltransferase 
Inhibition is not well characterized for the UGT enzymes.  Experiments often 
indicate a general decrease in UGT activity without specifically identifying the isoform 
involved.  Endogenous substrates, such as T3 and growth hormone82,83, can inhibit UGT 
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activity, likely as a feedback mechanism.  Inhibition of UGT can be caused by CYP84 
and/or phase II conjugates85. 
 
1.4.3.4 Glutathione-S-Transferase 
 The majority of research in the area of GST inhibition has involved the 
development of anticancer drugs, since GST induction is associated with multi-drug 
resistance in tumours86.  The structure of many GST inhibitors are quinones52.  
Irreversible inhibition of GST is observed with penicillin52. 
 
1.4.3.5 Natural Products as Inhibitors 
Cytochrome P450 inhibition by natural compounds is more common than 
inhibition of phase II enzymes, although this may be due to experimental design rather 
than natural compound mechanisms of action.  Table 1.4 gives some common examples 
of NHPs that cause drug metabolizing enzyme inhibition.  Currently there is little 
literature evidence documenting GST inhibition following exposure to naturally 
occurring compounds.   
 
Table 1.4: Common compounds in foods and natural health products that inhibit 
cytochrome P450 and uridine diphosphate-glucuronosyltransferase isoforms70,85,87-91 
Compound Source Metabolic Enzyme Inhibited 
Tumeric Spice CYP1A1/2  CYP2B1 
Silybin Milk Thistle CYP3A4 CYP2C9 
Thonningianins 
A and B Thonningia sanguinea 
CYP3A2 
CYP1A2 
Saffrole Sassafras Oil Black Pepper 
CYP1A2 
CYP2E1 
Palmitoyl-CoA Endogenous UGT 
Piperine Black Pepper UGT 
Resveratrol Grapes UGT 
Silymarin Milk Thistle UGT 
Phenethyl isothiocyanate Cruciferous vegetables UGT 
CYP = cytochrome P450, UGT = uridine diphosphate-glucuronosyltransferase 
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1.4.4 Natural Product Drug Interactions 
Natural compounds that cause induction or inhibition can result in drug 
interactions.  For example, compounds that induce CYP3A will increase detoxification 
of CYP3A substrates, decreasing systemic drug concentrations and pharmacological 
effect.  Alternatively, drugs like flucloxacillin, which undergo bioactivation by CYP3A 
will have enhanced toxicity92.  Similar alterations in drug concentration and/or 
bioactivation are possible with enzyme inhibition.  Inhibition of intestinal CYP3A4 by 
grapefruit can lead to increased circulation levels of amiodarone and other CYP3A4 
substrates that have high first pass metabolism93.  The potential for drug interactions is 
of particular importance with lignan supplementation, since the target population 
(patients with CVD, cancer and diabetes) are likely on other medications. 
 
1.5 Lignans as Inducers and Inhibitors of Drug Metabolizing Enzymes 
1.5.1 Induction of Cytochrome P450 and Phase II Enzymes 
Lignans are likely to be inducers of phase I and II enzymes because they undergo 
enterohepatic circulation, are substrates of CYP and phase II enzymes, have been 
demonstrated to interact with human PXR and similar compounds have shown enzyme 
induction.  Plant and mammalian lignans undergo enterohepatic circulation (see section 
1.3.4). Consequently, the intestine and liver are exposed to prolonged and high levels of 
lignan that may be significantly greater than systemic levels.  Most inducers and 
inhibitors are also substrates for oxidative metabolism.  Plant lignans are substrates of 
CYP and UGT enzymes, although it is not the major pathway of elimination. 
Secoisolariciresinol is a weak, and ENL a moderate agonist of human PXR.  In 
this study, the 10 μM dose of SECO administered to transfected cells indicates that 
chronic exposure to lignans may alter metabolism of drugs that are CYP3A substrates10.  
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More research is clearly needed on the induction potential of SECO and ENL/END on 
other phase I and II enzymes. 
Many compounds structurally similar to the flaxseed lignans are known inducers.  
The statin drugs have their primary site of action in the GIT.  Simvastatin induces 
CYP2B6 and CYP3A.  However, pravastatin does not affect CYP enzymes8.  This 
provides additional support that the lignans show potential for enzyme induction.  
However, results from the statin family demonstrate that structure based predictions are 
not definitive8.  Lignans isolated from Fructus schizandrae can induce phase II 
enzymes, superoxide dismutase and catalase, enzymes important in reducing oxidative 
stress94.  The structure of simvastatin and schisandrin (a lignan from Fructus 
schizandrae) are shown in Figure 1.2.   
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Figure 1.2: Chemical structure of cytochrome P450 inducers; A) simvastatin (top) or 
cytochrome P450 inhibitors, B) (-) dihydroclusin (a methylenedioxyphenyl lignan), C) 
sesamin (a sesame lignan), D) Bisphenol A, E) silybin and F) nordihydroguaiaretic acid 
(middle) and Phase II inducer and CYP inhibitor, G) schisandrin (a lignan from Fructus 
schizandrae) (bottom) 
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1.5.2 Inhibition of Cytochrome P450 and Phase II Enzymes 
The primary evidence for inhibition of CYP by SECO and SDG is the inhibition 
observed with other lignans.  Figure 1.2 shows the structures of these similar lignans.  
Methylenedioxyphenyl lignans are mechanism-based inhibitors of CYP3A495.  
Preliminary studies indicate that lignans in sesame inhibit CYP3A in vivo96,97.  The 
flavonolignan Silybin shows mechanism-based inhibition of CYP3A4 and CYP2C998 as 
well as potent anti-CYP1A activity99.  Nordihydroguaiaretic acid, a structurally similar 
lignan, also shows broad spectrum inhibition against CYP, particularly CYP1A100.  
Lignans isolated from Fructus schizandrae also inhibit CYP enzymes101.  Bisphenol A is 
an estrogenic compound that is a poor substrate for CYPs, but can inhibit CYP2C117. 
 
1.6 Methods of Assessment of Induction and Inhibition of Drug Metabolizing Enzymes 
by the Plant Lignans In Vitro 
1.6.1 Model Systems Used in the Assessment of Drug Metabolizing Enzyme Effects 
1.6.1.1 Rat Primary Hepatocytes 
Primary hepatocytes are fully functioning, metabolically active liver cells57.  
They are isolated from fresh tissue and grown in culture.  Because the cells remain 
intact, substrate specificity and induction and inhibition of drug metabolizing enzymes 
can be examined.  Rat primary hepatocytes are the gold standard for examining 
induction in vitro because they contain transcriptional machinery, intact membranes, 
protein degradation enzymes and transporters.  The protein degradation enzymes are 
necessary if induction occurs through protein stabilization.  Transporters and intact 
membranes govern the entrance of a compound into a cell. 
Other cell-based systems are used to assess induction.  Reporter gene assays 
examine the effect of a compound on a specific transcription factor102.  These assays 
have high throughput102 but may miss increased activity resulting from induction cross-
talk and similarities in ligand binding domains58,63. 
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1.6.1.2 Microsomes 
Inhibition assessments of drug metabolizing enzymes in vitro require active 
protein but not intact cell membranes.  The presence of intact cell membranes and 
transporters increases the in vivo relevance of studies, but is not required.  Hepatic 
microsomes are isolated from liver samples by differential centrifugation to isolate the 
subcellular fraction containing the enzymes of interest.  The use of the cytosolic or 
microsomal fraction depends on the subcellular location of the enzyme.  Specifically, 
microsomes are used to assess UGT and CYP activity, while the cytosol is used for GST 
enzyme activity.  The proteins remain metabolically active but induction and inhibition 
via gene transcription does not occur because there are no functional membranes45. 
 
1.6.2 In vitro Assessment of Induction of Drug Metabolizing Enzymes 
1.6.2.1 Real-time Reverse Transcription – Polymerase Chain Reaction 
There are multiple ways to screen for enzyme induction following exposure to 
SECO and SDG.  Real-time reverse transcription-polymerase chain reaction (RT-PCR), 
also called quantitative RT-PCR (qRT-PCR), detects mRNA levels103.  Relative 
quantitation (or semi-quantitation) is used to compare the amount of starting material in 
a sample to a negative control103.   As the name implies, real-time RT-PCR involves 
reverse transcription of the target gene into DNA, followed by exponential amplification 
by a heat stable DNA polymerase, such as Taq DNA polymerase103.   
To determine mRNA levels in “real-time”, a DNA binding dye, such as SYBR 
green, or gene-specific fluorescent probes, such as Taqman probes, are used.  The degree 
of fluorescence of either chemistry is directly related to the amount of starting material, 
making real-time RT-PCR a sensitive measure of gene levels103.  SYBR green chemistry 
is non-specific, which decreases assay setup and design cost but can generate false 
 25
positive signals without careful primer design.  Conversely, Taqman probes do not 
generate false positives but require specific probes for each gene target103. 
The major limitation of real time RT-PCR is that it may over or under-represent 
induction.  Increases in mRNA levels do not necessarily correlate to an increase in 
enzyme levels and activity.  Conversely, a lack of response may not indicate a lack of 
effect, as induction may also occur through other methods, such as protein stabilization. 
 
Table 1.5: Relationship between induction response for enzyme activity, mRNA and 
protein levels for cytochrome P450 following exposure to classical inducers in rat liver 
tissue 
Substance Activity Levels 
mRNA 
Levels 
Protein 
Levels 
Phenobarbital CYP1A1/2
CYP2B1/2 
CYP2E1 
CYP3A1 
 
CYP2B1/2 
 
CYP3A1 
 
CYP2B1/2 
 
CYP3A1 
β-Naphthoflavone CYP1A1/2 CYP1A1/2 CYP1A1 
Dexamethasone CYP3A1 CYP3A1 
CYP4A1 
CYP3A1 
Clofibrate CYP2E1 
CYP3A1 
CYP4A1 
 
CYP3A1/2
CYP4A1 
 
CYP3A1 
CYP4A1 
CYP2C11 
CYP = cytochrome P450 
 
 
As Table 1.5 indicates, activity, mRNA and protein levels correlate following 
induction of most rat enzymes.  In humans, there is an established relationship between 
mRNA induction and increased activity for CYP1A1 and 1A2 but not CYP2B6 and 
2D645.  Thus, real time RT-PCR is sufficient for preliminary studies of lignan induction 
as it is quick and requires only one instrumental method. 
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1.6.2.2 Cytochrome P450, Uridine Diphosphate-Glucuronosyltransferase and 
Glutathione-S-Transferase Gene Targets for Induction 
In the majority of mammalian test species, the major CYP families are CYP1A, 
2B, 2C, 2D and 3A.  However, the most active or prevalent isoform often differs45.  
Phase II enzymes show similar species differences.  Rat and human enzymes also show 
differences in induction potential104 and degree105 in response to an inducer.  Interspecies 
differences in induction are likely due to differences in the ligand binding domain45.  
Despite these differences, many test compounds show similar induction patterns. 
The methodology for the selection of CYP target genes in rats is outlined in this 
section.  The chosen genes are relevant markers of human enzymes.  A wide range of 
CYP genes were chosen as potential targets for lignan induction.  In particular, enzymes 
were chosen that are known to be readily inducible, are involved in the metabolism of 
current human pharmaceuticals, and those enzymes that often bioactivate chemicals into 
carcinogens.  The literature on NHPs often focuses on these common CYP isoforms, and 
they are likely candidates for lignan induction. 
 The rat UGT enzymes that glucuronidate steroids (UGT2B) and have higher 
prevalence in females were chosen as potential targets for induction by lignans, because 
lignans may interact via estrogen pathways18.  Similarly, UGT1A family genes were 
chosen that show high intestinal levels because the intestine has high exposure to 
lignans.  A review of the literature on GST induction following exposure to NHPs 
indicated the prevalent isoforms induced are the GSTA family, GSTP1 and GSTM.   
 
1.6.3 In vitro Assessment of Inhibition of Drug Metabolizing Enzymes 
1.6.3.1 Activity Assays 
Drug metabolizing enzyme inhibition usually occurs through direct enzyme 
interactions.  Thus, decreased protein activity is measured through the use of probe 
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substrates.  These compounds are substrates for specific isoforms, and metabolized to an 
identifiable, unique compound, which serves as a marker for enzyme activity.  The 
primary drawbacks to activity assays are that they require the use of substrates that are 
metabolized by specific isoforms, the use of additional cofactors and the presence of 
non-selectivity106.  Several specific CYP, UGT and GST isoforms have yet to have 
specific probe substrates identified. 
 
1.6.3.2 Cytochrome P450, Uridine Diphosphate-Glucuronosyltransferase and 
Glutathione-S-Transferase Isoforms as Targets for Inhibition 
 Testosterone metabolism can assess inhibition of multiple CYP isoforms in one 
assay, and is used as a general screen for inhibition.  Inhibition is uncommon with UGT 
and GST and preliminary screens of natural product effects do not include phase II 
activity assays.  Thus, a preliminary screen of lignan inhibition of drug metabolizing 
enzymes will focus on the major CYPs in the rat. 
 
1.7 Model Animal System 
The use of a model animal system has many advantages over the use of human 
tissue directly.  This is particularly true for the study of lignan induction and inhibition.  
The rat has well characterized drug metabolizing enzymes in comparison to humans, is a 
homogenous population, is used to study disease models related to lignan effects and has 
similar PK. 
 
1.7.1 Ease of Handling and Extrapolation 
Animal models have several advantages, most notably, ease of handling, housing 
and testing.  Other benefits include invasiveness of endpoints, homogenous populations 
and availability of tissue.  One of the most important benefits of using an experimental 
animal species is the lower degree of interindividual variability (polymorphisms and 
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environmental exposures) relative to the human population, which allows for more 
consistent results when examining induction and inhibition of hepatic enzymes57.  Phase 
II enzymes show similar individual variations and rat hepatocytes are considered a better 
model for UGT capacity57 and induction potential107.     
In comparison to other animal models, the rat is particularly useful because it is 
physiologically well characterized.  Experimental protocols are well documented, thus 
many variables in experimental design are obtainable from the literature.  It is one of the 
most common test species in the literature, allowing for easier comparison between 
studies and extrapolation both from in vitro to in vivo situations and from animals to 
humans.  The physiological data known about the rat provides a framework for 
determining the significance of the results.   
 
1.7.2 Pharmacokinetics and Pharmacodynamics of Plant Lignans 
Rats and humans share important similarities in flaxseed and lignan PK.  These 
similarities were outlined in section 1.3.4.5.  Thus, the rat is a good model to examine 
flaxseed.  Rats are also commonly used to examine the beneficial effects of flaxseed and 
the lignans, as noted in section 1.3.2.  Consequently, examining flaxseed lignan enzyme 
induction and inhibition in the rat will be of particular importance to human medicine.  
The rat is often used as a model system for toxicological, PK and nutrition studies, thus 
results obtained will be valuable for future studies and able to be extrapolated to 
humans.   
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CHAPTER 2 
2. Purpose of Project 
2.1 Rationale 
 Enzyme induction and inhibition by SECO and SDG may cause serious 
consequences, such as drug interactions and increased cancer risk.  The benefits of 
lignan use in the treatment and prevention of various diseases, such as CVD, diabetes 
and cancer, requires a thorough understanding of the potential for these serious 
consequences.  There is ample evidence in the literature to support the investigation of 
SECO and SDG as inducers and inhibitors of CYP, UGT and GST.  Therefore, the 
purpose of this project was to screen for induction and inhibition of various drug 
metabolizing enzymes by SECO and SDG, to predict the likelihood of drug interactions.  
To fulfill this purpose, several objectives were met: 
 
2.2 Objectives 
2.2.1 Objective 1 
To use rat liver microsomes to identify CYP inhibition in the presence of 
secoisolariciresinol or secoisolariciresinol diglucoside. 
 
2.2.1.1 Specific Aim 1 
To establish and validate a method to separate and quantitate 6β-, 16α- and 2α-
OH testosterone, as a measure of CYP3A, 2B/2C11 and 2C11 activity, respectively. 
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2.2.1.2 Specific Aim 2 
To determine if SECO and SDG inhibition was present and altered in a 
concentration and preincubation time dependent manner (irreversible inhibition) or a 
concentration and substrate (testosterone) concentration dependent manner (reversible 
inhibition) 
 
2.2.2 Objective 2 
 To develop a pre-eminent in vitro model system to determine the drug 
metabolizing enzyme transcriptional induction potential of SECO and SDG.    
 
2.2.2.1 Specific Aim 1 
To design primers that allow for the quantitation of transcriptional upregulation 
of CYP1A1, 2B1, 2C11, 2C13, 2D1, 2D2, 3A1 and 3A2, GSTA2, A5 and P1, and 
UGT1A1, 1A7, 1A8, 2B1 and 2B12 genes.  These primers provide efficient and specific 
amplification of the target gene using real-time RT-PCR on the Cepheid SmartCycler 
platform 
 
2.2.2.2 Specific Aim 2 
To isolate, separate and culture viable rat primary hepatocytes that are inducible 
by classic CYP inducers, ensuring an in vitro model system that can screen for lignan 
induction potential. 
 
2.3 Hypothesis 
Secoisolariciresinol and secoisolariciresinol diglucoside will induce and inhibit 
cytochrome P450 enzyme activity in rat hepatic microsomes. 
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CHAPTER 3 
3. Materials and Methods 
3.1 Materials 
3.1.1 Chemicals 
Acetaminophen, NADPH, Trifluoroacetic acid (TFA), Folin and Ciocalteu’s 
Phenol Reagent, 2.0N, Testosterone, 6β-OH testosterone, 2α-OH testosterone, 
Dimethylphenylacetone (DMPA), William’s E Media, Percoll, RNAlater, RNase Zap, 
HEPES, Dimethylsulfoxide (DMSO), Trypan Blue, Molecular Weight Marker - pUC18 
DNA Msp I digest, Dexamethasone (DEX), β-Naphthoflavone (βNF), Dispase II, neutral 
protease from Bacillus polymyxa, grade II and tert-Butylhydroquinone (t-BHQ) were 
purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON).  16α-OH testosterone was 
purchased from Steraloids Inc. (Newport, RI).  All gases for animal manipulations and 
media aeration were purchased from Praxair (Edmonton, AB).  Collagenase type IV and 
Collagenase type III were purchased from Worthington Biochemical Corporation 
(Lakewood, NJ).  Dulbecco’s phosphate buffered saline, Hank’s balanced salt solution, 
Trizol, ultrapure agarose, fetal bovine serum (FBS) and antibiotic/antimycotic were 
purchased from Invitrogen (Carlsbad, CA).  SYBR green RT-PCR kits RNeasy Mini 
Kits and QIAshredder columns were purchased from Qiagen Inc. (Missasauga, ON). 
Dispase II and Liberase Blendzyme III were purchased from Roche Diagnostics (Laval, 
PQ).  Secoisolariciresinol and SDG were gifts from Agriculture and Agri-Food Canada 
(Dr. Alister Muir, University of Saskatchewan).  Phenobarbital was a gift from Dr. G. 
McKay.  Collagen coated plates were from BD Biosciences (Missassauga, ON).  
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Isoflurane, heparin and all surgical supplies were purchased from the Western College of 
Veterinary Medicine, University of Saskatchewan. 
All other chemicals were of the highest grade required for the experiments.  All 
solvents were high performance liquid chromatography (HPLC) grade.  All water used 
in experiments was filtered through a Millipore (0.22 μm) water purification system 
(Fisher Scientific Limited, Nepean, ON). 
 
3.1.2 Animals 
Male Sprague-Dawley (S-D) rats were purchased from Charles River 
Laboratories, Inc. (Saint-Constant, PQ) at approximately 200-250g for inhibition 
experiments or 13 weeks of age (~150g) for induction experiments.  Rats were housed in 
a temperature, humidity and 12 hour light-dark controlled facility at the College of 
Pharmacy and Nutrition, University of Saskatchewan.  Rats were allowed to acclimatize 
in the facility for at least one week and were fed standard laboratory rat chow, ad libitum 
and had free access to water.  All procedures were approved by the University 
Committee on Animal Care and Supply at the University of Saskatchewan. 
 
3.2 Inhibition of Cytochrome P450 (CYP) 3A, 2B and 2C11 by the Flaxseed Plant 
Lignans Secoisolariciresinol Diglucoside and Secoisolariciresinol 
3.2.1 Preparation of Hepatic Microsomes for Inhibition Experiments 
Rats (n=4) were anesthetized with isoflurane and a midline incision made to 
expose the abdominal cavity.  The portal vein was isolated and cannulated with a 20g 1 
¼” Terumo Surflo I.V. catheter.  The vena cava was nicked to allow blood and perfusate 
outflow.  The livers were perfused via the portal vein with room temperature phosphate 
buffered saline (PBS) until the liver cleared and no blood was visible exiting the vena 
cava.  Livers were removed and rinsed in PBS.  Livers were weighed into 3 or 6 g pieces 
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and immediately flash frozen in liquid nitrogen and stored at -80°C until microsomal 
preparation.   
Microsomes were prepared by differential centrifugation according to the method 
of Iba et al.108.  Briefly, tissues were homogenized with a teflon pestle in a glass sleeve 
in homogenization buffer (0.1 mM phenylmethylsulfonylflouride, 50mM Tris buffer, 
150 mM KCl, 0.1 mM dithiothreitol, 1 mM ethylenediamine tetracetic acid and 20% 
glycerol) until homogeneous.  The mixture was transferred to a Beckman (Beckman 
Coulter Canada, Inc. Mississauga, ON) ultracentrifuge tube and spun in a Beckman L8-
55 Ultracentrifuge with a Ti-70 rotor at 9000g for 30 minutes at 4°C.  The supernatant, 
which contains both cytosolic and endoplasmic reticulum components, was transferred 
into clean ultracentrifuge tubes and spun at 100 000g for 30 minutes at 4°C.  The pellet 
was washed with 150 mM KCl then similarly spun for an additional 30 minutes at 4°C.  
The pellet was reconstituted in 0.25 M sucrose and passed through a syringe.  The 
microsomes were pooled (n = 4) at this point and stored at -80°C.  Samples were only 
used after one thaw.   
 
3.2.2 Determination of Hepatic Microsomal Protein and Cytochrome P450 Content 
Microsomal protein content was determined by the method of Lowry et al.109.  
Briefly, microsomes were diluted 1:50 in 0.5M NaOH.  To samples containing 0, 0.2, 
0.4, 0.6 0.8 or 1.0 mL diluted microsomes (final volume 1 mL with 0.5 M NaOH) 5 mL 
of copper reagent (0.01% copper sulphate, 0.02% sodium potassium tartarate, 99.97% 
sodium carbonate) was added.  After 10 minutes, 0.5 mL of Folin’s reagent (1:2 dilution 
with H2O) was added and samples stood for an additional 30 minutes.  Absorbance was 
determined in an UV/Vis spectrophotometer (#8453E, Agilent Technologies, Palo Alto, 
 34
CA) at 750 nm.  Samples were compared to a similarly prepared bovine serum albumin 
standard curve to determine protein content. 
Cytochrome P450 content was determined using the method of Omura and 
Sato110.  Microsomes were thawed on ice and diluted to 1mg/mL in a quartz cuvette.  A 
few mg of hydrosulphite was added and CO gas bubbled at a rate of three bubbles per 
second for 30 seconds.  From absorbance measurements at 420, 450 and 490 nm in an 
UV/Vis spectrophotometer, the CYP content was determined. 
 
3.2.3 Validation of a High Performance Liquid Chromatography Testosterone 
Metabolism Assay to Assess Changes in Enzyme Activity 
In order to assess changes in metabolite profiles following exposure of hepatic 
microsomes to SECO and SDG, a high performance liquid chromatography (HPLC) 
method was adapted from the literature and validated.  The testosterone assay was 
intended to be a general screening method to detect changes in activity of several 
specific CYP isoforms.  Specifically, the activity of CYP3A, 2B/2C11 and 2C11 were 
monitored by measuring the formation of 6β-, 16α- and 2α-hydroxytestosterone, 
respectively.  
 
3.2.3.1 Determination of an Appropriate Testosterone High Performance Liquid 
Chromatography Method to Detect Changes in 6β-, 16α- and 2α-OH 
Testosterone Formation 
Initial attempts to establish a valid HPLC method for testosterone metabolites 
were based upon modifications of Sanwald et al.111 and Reinerink et al.112.  These 
methods failed to adequately resolve the essential hydroxylated metabolites, internal 
standard and parent compound, testosterone, to allow for specific quantification of the 
desired testosterone metabolites.  However, modifications of Pfeiffer and Metzler 7, led 
to appropriate chromatography.   
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Chromatographic conditions consisted of an Alliance HPLC system with a 
Waters (Milford, MA) separation module 2695 and Photodiode Array Detector 2996.  
The column was a Waters HPLC Nova-Pak C18 60Ǻ column (3.9 mm × 150 mm, 5μm) 
with a 7.5 mm × 4.6 mm Allsphere ODS2 C18 5μm guard column.   The mobile phase 
was acetonitrile (ACN) and H2O as solvents A and B, respectively.  Both solvents 
contained 0.1% trifluoroacetic acid (TFA).  Optimum chromatography required a linear 
gradient from 0 to 35 minutes from 20-75% solvent A, and a linear gradient from 35 to 
40 minutes from 75% - 100% solvent A.  The flow rate was 1.0 mL/min and absorbance 
was monitored at 240 nm.  For all calibration and unknown samples, 150 μL was 
injected onto the HPLC system.     
 
3.2.3.2 Preparation of Stock Solutions of Testosterone and Metabolite Standards 
Testosterone was prepared as a 125mM stock in methanol using the Mettler 
(Mettler-Toledo Inc. Columbus, OH) UM3 ultra microbalance (calibration 10 mg ± -1 
μg).  Stock solutions were made for 6β-, 16α- and 2α-OH testosterone using the ultra 
microbalance and diluted in methanol to 5 mM based on published information111.  All 
of the stock solutions were stored in amber bottles at -20°C.   
 
3.2.3.3 Testosterone High Performance Liquid Chromatography Assay Validation 
Testosterone HPLC assay validation procedures were performed according to the 
Food and Drug Administration (FDA) guidelines113.  Specificity (the absence of 
endogenous compounds coeluting with the metabolites of interest) was determined 
following analysis of four different rat hepatic microsomal preparations.  The linearity of 
the method was evaluated by processing 9 calibration standards (in triplicate) added at 
known concentrations (ranging from 0.4 to 200 μM) to microsomal incubation mixtures 
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containing heat-inactivated (95°C for 5 min) microsomes on different days. The 
calibration curve was constructed from the plot of peak height ratios (of the detector 
absorbance response) between metabolite and the internal standard and the nominal 
concentration of the metabolite.  
A linear least-squares regression analysis allowed estimation of the slope, 
intercept and coefficient of determination (r2).  Limit of quantitation (LOQ) was 
determined at the lowest concentration at which the precision was less than 20% and 
accuracy was within 20%. Precision was expressed as % relative standard deviation 
(RSD), while accuracy (%) was expressed as relative difference between the measured 
and nominal value.  The intra-day accuracy and precision were assessed from the results 
of six replicate analyses of quality control (QC) samples (low, medium and high) on a 
single assay day.  The inter-day accuracy and precision were determined from the same 
QC samples analyzed over three days.    
 
3.2.4 Determination of Cytochrome P450 (CYP) 3A, 2B and 2C11 Inhibition 
Mechanism by the Flaxseed Plant Lignans Secoisolariciresinol Diglucoside and 
Secoisolariciresinol 
In order to determine whether SDG and/or SECO are inhibitors of CYP3A, 2B 
and 2C11 activity, experiments were carried out in a microsomal test system to 
determine the mechanism.  Preliminary experiments examining protein and time-
dependent metabolite formation kinetics indicated that microsomal incubations 
containing 0.5 mg/mL protein and incubated with testosterone for 15 minutes gave linear 
metabolite formation velocities.  This is similar to the linear conditions reported by 
Vuppugalla and Mehvar114.  
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3.2.4.1 Time and Concentration Dependent Inhibition (Irreversible Inhibition) of 
CYP3A, CYP2B and CYP2C11 by the Flaxseed Plant Lignans 
Secoisolariciresinol Diglucoside and Secoisolariciresinol  
Irreversible inhibitors decrease CYP activity in both a concentration- and pre-
incubation time-dependent manner.  This type of inhibition is examined first when the 
mechanism of inhibition is unknown.  Guidelines for study design are outlined by the 
FDA115.   The microsomal incubation mixture consisted of protein (0.5 mg/mL), MgCl2 
(5 mM) and NADPH (1 mM) in phosphate buffer.  The final concentration of 
testosterone was 250 μM.  Inhibitor stock solutions were made up by adding SECO or 
SDG into phosphate buffer (80 mM, pH 7.4) for a final concentration of 2.475 mM and 
1.238 mM respectively. Serial dilutions in phosphate buffer gave working solutions of 
1.856, 1.238 and 0.6188 mM for SECO and 0.6188, 0.3094 and 0.1238 mM for SDG.   
Microsomal incubation samples were prepared in triplicate with 0, 500, 1000, 
1500 or 2000 μM SECO or 0, 100, 250, 500 or 1000 μM SDG in the microsomal system 
containing protein, MgCl2 and phosphate buffer.  Tubes were placed in a shaking water 
bath at 37°C.  After 5 minutes, NADPH (10 mM) was added and mixtures were allowed 
to incubate for 0, 5, 10 or 20 minutes before the addition of testosterone.  Following 
testosterone addition the samples were incubated at 37°C for an additional 15 minutes.  
The reaction was halted by immersing the tubes in ice and adding 50 μL of ice cold 
ACN containing 100 μM acetaminophen or 1 mM dimethylphenylacetone (DMPA) as 
the internal standard for SECO or SDG, respectively.  Samples were centrifuged for 10 
minutes at 14000 rpm and the supernatant transferred to HPLC sample vials.  Heat 
inactivated microsomes and tubes containing no NADPH were used as negative 
controls. 
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3.2.4.2 Substrate and Inhibitor Concentration Dependent Inhibition (Reversible 
Inhibition) of CYP3A, CYP2B and CYP2C11 by Secoisolariciresinol 
Reversible inhibition, characterized by a decrease in enzyme activity with 
increasing inhibitor concentration, can be competitive, noncompetitive or uncompetitive.  
To determine the mechanism of reversible inhibition, microsomes were incubated with 
various concentrations of inhibitor (SECO) and substrate (testosterone).   
A SECO stock solution (prepared that day) was diluted with phosphate buffer (pH 7.4) 
to give a final concentration in the reaction mixture of 0, 10, 25, 50, 100, 200, 400, 800 
or 1600 μM.  The microsomal incubation mixture consisted of MgCl2 (5 mM), 
microsomal protein (0.5 mg/mL), NADPH (1 mM) in phosphate buffer (pH 7.4).  
Testosterone working solutions were prepared in methanol so that a 4 μL addition would 
result in a final concentration of 0, 25, 50, 100 or 250 μM, representing the approximate 
values of 1/2KM, KM, 2KM and the VMax concentrations respectively114.    
All microsomal incubation samples, performed in triplicate, were preincubated 
for 3 minutes in a shaking water bath at 37°C before addition of NADPH to initiate the 
reaction.  After a 15 minute incubation period the reaction was halted by the addition of 
ice cold ACN containing acetaminophen (100 μM).  Samples were centrifuged at 14000 
rpm for 10 minutes and the supernatant transferred to HPLC sample vials.  Negative 
control samples included heat inactivated microsomes and reaction mixtures containing 
no NADPH.   
 
3.2.4.3 Statistical Analysis 
Prior to sample analysis, a nine point standard curve was run in triplicate.  
Quality control samples at three or four different concentrations were randomly 
interspersed throughout the run.  The peak height value for each metabolite and the 
internal standard was determined either by the software or manual integration following 
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a 150 μL injection.  Peak height ratios of metabolite to internal standard were calculated 
for samples and controls, and the concentration of metabolite interpolated from the 
standard curve.  For each inhibitor concentration, the percent of control activity (% 
inhibition) was determined.   
For irreversible inhibition studies, the % inhibition of activity for each inhibitor 
concentration was plotted versus pre-incubation time using Microsoft Excel (Seattle, 
WA).  For reversible inhibition studies, % inhibition of activity at each substrate 
concentration was plotted versus the inhibitor concentration.  Inhibition graphs and 
Lineweaver-Burke plots (inverse enzyme velocity versus inverse substrate 
concentration) were generated using Microsoft Excel.  All samples are represented as the 
mean ± S.D. (standard deviation). 
 
3.3 Development of a Method to Assess Phase I and Phase II Enzyme Induction in Rat 
Primary Hepatocytes 
3.3.1 Development of Real-Time Reverse-Transcription-Polymerase Chain Reaction 
Assays to Assess Cytochrome P450 and Phase II Enzyme Induction in Rat Primary 
Hepatocytes 
Cytochrome P450 and Phase II enzyme mRNA induction was assessed using the 
Cepheid SmartCycler platform (Cepheid, Sunnyvale, CA). The literature review outlined 
the rationale behind target gene selection.  Target gene sequences were obtained from 
the National Centre for Biotechnology Information (NCBI) Genbank database 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=nucleotide) via 
nucleotide searches for both new and outdated nomenclature.  Nucleotide sequences 
were inputed into Primer 3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and ideal primers were designed based on criteria for 
optimal amplification by the Cepheid SmartCycler and QIAGEN SYBR green RT-PCR 
kits.   
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Optimum primer design conditions included the following: a primer nucleotide 
sequence between 18 and 22 base pairs with 58-62% G or C bases, a primer melt 
temperature between 58 and 62°C, a product size between 150-200 base pairs, a 
maximum 3’ complementarity of 3 and a GC clamp of two.  A GC% greater than 50% 
of the nucleotides in the primer sequence increases binding fidelity but can lead to non-
specific binding when greater than 62%, since many DNA sequences contain GC rich 
areas.  Similarly, a GC clamp of two is used to ensure that the last two bases are G or C 
for increased affinity.  The 3’ complementarity indicates the number of 3’ primer sites of 
alignment.  A lower 3’ complementarity decreases the probability of forming primer-
dimers during PCR cycling.  Primer-dimers result in the formation of a second product 
and decreases amplification efficiency of the target gene.  A rodent mispriming library 
was searched to determine if the primer sequences had similarity to other nontarget 
genome sequences. 
 All primers were ordered from Invitrogen.  Left and right primers were 
reconstituted separately in RNase/DNase free water to give a concentration of 50 μM.  
This stock solution was further diluted to 12.5 μM in separate tubes to minimize 
repeated free-thaw cycles. 
  
3.3.2 Control RNA Extraction and Quantitation for Optimization of Real-Time Reverse 
Transcription-Polymerase Chain Reaction Assays 
3.3.2.1 Isolation of Total RNA from Control Male and Female Liver and Lung Tissue 
Liver and lung tissues for construction of real-time calibration curves (female 
Wistar or S-D rats) were surgically removed from anaesthetized (isoflurane) rats and 
immediately immersed in RNA Later solution and stored at –20°C. Total liver and lung 
RNA was isolated using RNeasy Midi kits according to the manufacturer’s instructions.  
Briefly, 240-250 mg of tissue was weighed and 4 mL of RLT buffer (containing β-
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mercaptoethanol) was added.  The sample was homogenized and centrifuged in an 
Eppendorf (Eppendorf, Westbury, NY) centrifuge (model #5804R) for 10 minutes at 
4,500g at room temperature.  The supernatant was transferred to a new tube, 1 volume of 
70% ethanol was added, and the mixture was shaken.  Samples were added to the midi 
column and spun for10 minutes at 4,500g at room temperature.  Samples were washed 
with 1 volume of RWI buffer and then 2.5 μL of RPE buffer twice.  The column was 
transferred to a new tube and the RNA was eluted with 150 μL RNase free H2O. 
 
3.3.2.2 Determination of Total RNA Purity and Yield 
Total RNA was diluted 1:100 in Tris-HCL buffer (pH 7.5) and absorbance at 260 
and 280 nm was determined spectrophotometrically. An A260/A280 ratio between 1.9-2.1 
was considered adequate (containing minimal protein and/or phenol contamination) for 
real-time RT-PCR assays.   Total RNA was quantified by diluting the total RNA sample 
1:100 with RNAse free water and measuring absorbance at 260 nm with an UV/Vis 
spectrophotometer (Equation 3.1). 
 
CRNA (μg/mL) = 40 μg/mL × A260 × Dilution factor    (3.1) 
 
The dilution factor is 100 and an A260 = 1 corresponds to 40 μg/mL RNA. 
 
3.3.3 Real-Time Reverse Transcription-Polymerase Chain Reaction Assessment of 
Primer Sets for Optimal Gene Amplification 
To assess the viability of the chosen primer sets, primer tests were conducted as 
outlined below. 
 
3.3.3.1 Selection of Appropriate Primers Based on Real-Time Reverse Transcription-
Polymerase Chain Reaction Amplification 
The SYBR green (1X), reverse transcription (RT) mix (1X) and primers (1 μM) 
were diluted in RNase free water to a final volume of 23 μL.  2 μL RNA (50 μg) was 
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added to real-time RT-PCR samples.  Non-template control (NTC) samples contained 
SYBR green, RT mix, primers and water but RNA free water rather than RNA.  These 
samples detect the formation of primer-dimers (amplification of primer sequences rather 
than DNA).  The gender and source of RNA for each primer set are listed in the results 
section.   
The samples were reverse transcribed by activation of the polymerase at 50°C for 
30 minutes and reverse transcription at 95°C for 15 minutes.  The target sequence was 
amplified over 40-50 cycles of primer dissociation (94°C for 15 sec), primer annealing 
(58°C for 30 sec) and primer elongation (72°C for 30 sec).  Changes in SYBR green 
fluorescence was measured in each cycle during the elongation phase.  Following 
amplification, the melting temperature of the sample was determined by measuring 
fluorescence while the sample temperature was increased to 95°C at a rate of 0.5°C per 
second.   
Following target sequence amplification, the Cepheid software calculated the 
cycle threshold (Ct) value.  The Ct value is the cycle number at which the sample 
fluorescence can be distinguished from background levels.  A second derivative graph, 
plotted by the software, of fluorescence vs. Ct was analyzed for differences between 
NTC and samples.  Ideal primers had NTC samples without fluorescence, indicating no 
primer-dimers were formed.   
Sample fluorescence versus sample temperature graphs generated by the 
software determined the melting temperature of the sample.  Primers were not 
acceptable if the NTC samples had a melt peak in the same region as the sample melt 
peak.  The sample melt peak should appear uniform indicating formation of a single 
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product.  Following amplification and melt curve analysis, all samples were frozen at -
20°C for agarose gel electrophoresis examination of product size. 
 
3.3.3.2 Determination of Primer Set Real-Time Reverse Transcription-Polymerase Chain 
Reaction Target Product Amplification by Agarose Gel Electrophoresis 
A 2% agarose gel was prepared in 1X TBE buffer (Tris Base, Boric Acid, 0.5 M 
ethylene diamine tetraacetic acid (EDTA) and H2O) in a midi-gel unit (C.B.S. Scientific 
Company, Inc., Del Mar, CA Model # MGU-502T).  Each sample and a molecular 
weight marker (bands at 501+489, 404, 353, 242, 190, 147, 110, 89, 67, 34 and 26), 
stained with loading dye (50 mM TRIS HCl pH 8, 50mM EDTA pH 8, 50% glycerol 
and 0.25% Bromophenol Blue) were mixed added to the agarose gel and run in 1X TBE 
buffer at 125 V for 90 minutes.  The gel was stained in H2O with ethidium bromide for 
20 minutes and the gel visualized with an AlphaImager (Alpha Innotech Corporation, 
San Leandro, CA).  The PCR products were examined for only single bands 
corresponding to the predicted product size for each respective primer set. 
 
3.3.4 Determination of Optimal Primer Sets for Target Gene Amplification by Real-
Time Reverse Transcription-Polymerase Chain Reaction 
Primer sets that gave rise to specific melt peaks with a single band (with 
expected amplicon size) on agarose gel electrophoresis were further evaluated for 
amplification efficiency. To determine if chosen primer sets amplified target genes 
efficiently, at least a three-point standard curve was generated in duplicate using control 
RNA with a final amount of 50, 5, 0.5 and/or 0.05 ng RNA per sample. Initial runs were 
all conducted with a primer annealing temperature of 58°C.  The temperature was varied 
between 56°C and 60°C to achieve optimal amplification.  The annealing temperature 
for each primer set is listed in the results section.  Standard curves were generated from 
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threshold cycle vs. log concentration graphs and the slope determined.  Efficiency was 
calculated according to equation 3.2.     
 
 Efficiency (E) = 10(-1/slope)       (3.2) 
 
Optimal efficiency is ~2.0, indicating that amplification occurs as a factor of 2 during 
cycling.  Only primer sets with 1.85 < E < 2.15 were considered acceptable. 
 
3.3.5 Isolation of Rat Primary Hepatocytes to use for Assessments of Cytochrome P450 
and Phase II Enzyme Induction 
Rat primary hepatocytes were isolated, cultured and harvested in order to assess 
in vitro induction of metabolic enzymes by SECO.  Modifications of various methods 
were used to obtain a suitable method.  Chapter 4 outlines the final procedure.  This 
section outlines the materials used in this procedure.   
 
3.3.5.1 Procedures Involved in the Isolation and Culture of Rat Primary Hepatocytes 
All buffers and media contained 1X antibiotic/antimycotic solution and were 
sterile filtered through a 0.2 μm membrane.  Any components added following filtration 
were filtered through a 0.2 μm syringe filter (Pall Life Sciences, East Hills, N.Y., 
product # 4192). All buffers were stored at 4°C  
William’s E media, with L-glutamine was reconstituted according to package 
instructions 1L at a time using filtered H2O and pH adjusted to ~7.1 - 7.3.  The method 
of Sinz 116 suggested the use of two perfusion buffers in the isolation of hepatocytes, 
which were prepared as 10X stock solutions and diluted immediately prior to perfusion.  
The first buffer contained sodium chloride (120 mM), potassium chloride (5.3 mM), 
sodium bicarbonate (7.4 mM), sodium hydrogen phosphate (0.3 mM), glucose (5.6 
mM), HEPES (10 mM) and ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetra 
acetic acid (EGTA, 0.5 mM).  The second perfusion buffer contained the same 
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components at the same concentrations except EGTA was substituted with calcium 
chloride (2.5 mM) to replace the calcium that was chelated by EGTA.  Both solutions 
were pH adjusted after aeration to 7.4. 
 Krebs-Henseleit buffer (KHB) was prepared according to instructions from 
Sigma.  This buffer was used in a method modified from Nicoll-Griffith et al.117 and 
contained D-glucose (2.0 g/L), anhydrous magnesium sulphate (0.141 g/L), potassium 
phosphate monobasic (0.16 g/L), potassium chloride (0.35 g/L), potassium chloride 
(0.35 g/L) and sodium chloride (6.9 g/L).   
 Roche Scientific buffers were prepared according to the manufacturer’s 
instructions for use with their Liberase Blendzyme III product in the dissociation of 
rodent hepatocytes.  The initial perfusion buffer consisted of sodium chloride (8.3 g/L), 
potassium chloride (0.5 g/L) and HEPES (2.4 g/L) and pH adjusted to 7.4 with 1 M 
sodium hydroxide.  The digestion buffer contained sodium chloride (3.9 g/L), potassium 
chloride (0.5 g/L), HEPES (24.0 g/L) and calcium chloride dihyrdate (0.7 g/L) pH 
adjusted to 7.6 with 1 M sodium hydroxide.  The suspension buffer contained sodium 
chloride (4.0 g/L), potassium chloride (0.4 g/L), HEPES (7.2 g/L), calcium chloride 
dehydrate (0.18 g/L), potassium phosphate monobasic (0.15 g/L), sodium sulphate (0.1 
g/L), magnesium chloride hexahydrate (0.13 g/L), TES (6.9 g/L), tricine (6.5 g/L) and 
sodium hydroxide (2.1 g/L) pH adjusted to 7.6 with 1 M sodium hydroxide.  The wash 
buffer contained sodium chloride (8.3 g/L), potassium chloride (0.5 g/L), HEPES (2.4 
g/L) and calcium chloride dehydrate (0.18 g/L) pH adjusted to 7.4 with 1 M sodium 
hydroxide.  The perfusion, digestion and suspension buffers were aerated with 
5%CO2/95%O2 for a minimum of 30 minutes, according to the protocol designed by the 
manufacturer. 
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3.3.5.2 General Procedure Used for the Isolation of Rat Primary Hepatocytes 
Following anesthesia (isoflurane), a midline abdominal incision was made and 
the portal vein and vena cava exposed.  Heparin was injected with a monoject 1mL 
tuberculin slip tip (25 5/8”) syringe into the vena cava.  After one minute, the portal vein 
was cannulated with a 20g 1 ¼” Terumo Surflo I.V. catheter and perfused using a Vario 
pump system by Cole-Parmer Instruments (Vernon Hills, Ill, model # 7337-00) with 
various buffers, containing different digestion enzymes (Collagenase, Blendzyme).  For 
more information on the isolation of rat primary hepatocytes, see Chapter 4. 
 
3.3.5.3 Determination of Cell Viability and Yield of Rat Primary Hepatocytes  
Viability and yield were assessed using the trypan blue exclusion method.  
Trypan blue was reconstituted according to manufacturer’s protocols in a 0.5% solution.  
Cells were diluted in wash buffer and added to 200 μL 0.5% trypan blue, to a final 
volume of 1 mL.  The final number of cells added to the trypan blue solution was 
between 100-1000 cells/mm3 on the haemocytometer118 (Hauser scientific, Boulder CO, 
model # 1483).  Cells were incubated in the trypan blue solution at room temperature for 
5 minutes before addition to a haematocytometer and counted using a culture 
microscope (Olympus, Center Valley, PA, Model # CKX31) according to the method 
outlined in Methods in tissue engineering118.  Briefly, the cover slip was wetted and 
pressed to the slide, a glass pipet was used to allow cells to be applied with capillary 
action and the cells were counted at 10X magnification.  Equation 3.3 was used to 
calculate cell yield with the appropriate dilution factor (DF) and the haematocytometer 
conversion factor (HC), which was 10. 
 
 # cells/square x DF x HC x 103 = # of cells/mL     (3.3) 
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Cell viability was obtained from comparison of live and dead cells, based on the 
exclusion of trypan blue in two separate trypan blue dilution preparations. 
 
3.3.5.4 Techniques for Plating and Culturing Rat Primary Hepatocytes 
Studies were completed to determine the rat hepatocyte plating conditions that 
would result in confluency, inducibility and sustained growth.  Cells were plated on 
various sized collagen coated plates (see results section for more information) with 
William’s E media and incubated at 37°C in a humidity controlled, 5% CO2 incubator 
(Thermo Electron Corporation, Forma series II, model 3110).  Cells were incubated for 
3 to 4 hours in William’s E media containing 10% fetal bovine serum (FBS) for cell 
attachment and attainment of confluency.  Following the attachment period, the media 
was aspirated and new William’s E media was added without FBS.  Throughout plating, 
100 nm basal DEX was added to mimic basal glucocorticoid levels, as this has been 
shown to increase cell responsiveness to induction116.  All media was supplemented with 
1X antibiotic/antimycotic.     
 
3.3.5.5 Determination of Enzyme Induction in Cultured Rat Primary Hepatocytes 
Dexamethasone (DEX), a CYP3A inducer, phenobarbital (PB), a CYP2B 
inducer, tert-butylhydroquinone (tBHQ), a general GST inducer and β-naphthoflavone 
(βNF), a CYP1A inducer, were diluted in dimethylsulfoxide (DMSO, final concentration 
less than 0.1% to prevent enzyme induction by the solvent115) and used as positive 
controls119.  All compounds were weighed out on the ultra microbalance and stored at -
20°C.  The final concentrations of positive control samples were based on literature 
accepted concentrations for transcriptional enzyme induction119.  Table 3.1 lists the stock 
and final concentrations used for induction of each positive control solution. 
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To determine if the hepatocyte culture conditions and positive controls were 
appropriate for measuring mRNA induction, cell cultures were assessed visually and for 
positive control mRNA levels.  Cell plates were examined visually via trypan blue 
exclusion for cell attachment and confluency following the attachment period, at media 
changes and before harvesting.  The positive control samples were diluted in William’s 
E media and added to the cell culture plates immediately following the attachment 
phase.    
 
 
Table 3.1: Initial and final concentrations of dexamethasone, phenobarbital, tert-
butylhydroquinone and β-naphthoflavone used to induce cytochrome P450 and phase II 
enzymes in primary rat hepatocytes 
 [Stock] mM [Final] μM 
Phenobarbital 400 100 
Dexamethasone 40 10 
β-Naphthoflavone 40 10 
tert-Butylhydroquinone 400 100 
 
 
 
3.3.5.6 Harvesting of Rat Primary Hepatocytes and Extraction of RNA 
Cultured hepatocytes were harvested from the collagen coated plates using a cell 
scraper (BD Falcon, 353985). Different procedures for total RNA isolation including 
trizol, RLT buffer and dispase II were attempted.  The final method used for RNA 
isolation was similar to that outlined in section 3.3.2.1 using QIAGEN RNeasy Mini 
kits.  Briefly, cells were passed through a QIAshredder column to lyse the cells and then 
buffers were added and spun (Eppendorf 5417C centrifuge) to clean and elute RNA 
according to manufacturer’s instructions.  For Trizol harvested cells, chloroform was 
used to extract the aqueous layer, and RNA was isolated using the manufacturer’s 
protocol.  The volumes of reagents were determined experimentally to give optimum 
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RNA yield and purity.  The results section, Chapter 4, details the cell harvesting and 
RNA isolation procedures. 
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CHAPTER 4 
4. Results 
4.1 Inhibition of 6β-, 16α- and 2α-OH Testosterone Formation by 
Secoisolariciresinol and Secoisolariciresinol Diglucoside 
4.1.1 High Performance Liquid Chromatography Method Validation Parameters for 
Quantification of Testosterone Metabolites 
To quantify 6β-, 16α- and 2α-OH testosterone formation in rat hepatic 
microsomes, an HPLC assay was adapted from the literature and validated according 
to FDA assay validation guidelines.  Figure 4.1 shows typical chromatograms from 
blank microsomal suspensions (Figure 4.1A), a calibration standard (Figure 4.1B), 
and a microsomal incubation at 50 μM testosterone (Figure 4.1C). 
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Figure 4.1: Representative high performance liquid chromatography chromatograms 
for the validation of 6β-, 16α- and 2α-OH testosterone, A) blank rat hepatic 
microsomes; B) quality control sample with internal standards, acetaminophen (3.7 
min) and dimethylphenylacetone (13.6 min); C) microsomal incubation with 
testosterone (50 μM); and D) inset showing metabolite peaks 
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Figure 4.1A indicates the lack of endogenous interfering peaks at retention 
times corresponding to testosterone metabolites and the internal standard confirming 
specificity of the chosen method. Figure 4.1B and 4.1C demonstrate the specificity 
and separation of the metabolites.  The mobile phase conditions resulted in 
retentions times of 19.8, 20.6 and 23.1 minutes for 6β-, 16α- and 2α-OH 
testosterone, respectively.  Peak height was used to calculate metabolite 
concentration due to slight overlapping peaks at concentrations above 20 μM to 
ensure accuracy and precision of the method.            
 
 
Table 4.1: Testosterone high performance liquid chromatography assay slope, y-
intercept and coefficient of determination for 6β-OH testosterone for four separate 
standard curves conducted in triplicate 
Standard Curves Slope y-intercept Coefficient of 
Determination (r2) 
1 0.0762 -0.0030 0.9998 
2 0.0807 -0.0035 1 
3 0.0814 -0.0068 1 
4 0.0922 0.0042 0.9999 
Average ± S.D. 0.0826 ± 0.0068  -0.0023 ± 0.005  
  
 
 
Table 4.2: Testosterone high performance liquid chromatography assay slope, y-
intercept and coefficient of determination for 16α-OH testosterone for four separate 
standard curves conducted in triplicate 
Standard Curves Slope y-intercept Coefficient of 
Determination (r2) 
1 0.0984 0.0082 0.9995 
2 0.1117 -0.0085 1 
3 0.1138 -0.0107 0.9999 
4 0.1035 -0.0038 0.9999 
Average ± S.D. 0.107 ± 0.0072 -0.0037 ± 0.008  
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Table 4.3: Testosterone high performance liquid chromatography assay slope, y-
intercept and coefficient of determination for 2α -OH testosterone for four separate 
standard curves conducted in triplicate 
Standard Curves Slope y-intercept Coefficient of 
Determination (r2) 
1 0.0851 0.0029 0.9994 
2 0.0941 0.0004 0.9998 
3 0.0996 -0.006 0.9997 
4 0.1135 -0.004 0.9998 
Average ± S.D. 0.0981 ± 0.012 -0.002 ± 0.004  
 
 
The method was linear over the testosterone metabolite concentration ranges 
of 0.4 μM to 25 μM, which was above metabolite concentrations following 
testosterone incubations. Coefficients of determination were greater than 0.999 and 
the relevant slope and y-intercept values were statistically different from zero (p < 
0.005). The LOQ was 0.4 μM for each metabolite.  6β-OH testosterone interday 
accuracy (% difference) and precision (CV%) were 3.36% and 14.7%, respectively.  
The interday accuracy and precision for the LOQ of 16α-OH testosterone were 
9.02% and 7.26%, respectively.  For 2α-OH testosterone, the interday accuracy and 
precision of the LOQ were 3.13% and 11.5%, respectively.  Tables 4.4 through 4.6 
outline the intra and interday accuracy and precision for each metabolite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54
Table 4.4: Inter-day (range over 3 days), and intra-day (mean ± S.D.) accuracy and 
precision values of 6β-OH testosterone following high performance liquid 
chromatography-ultraviolet detection in rat hepatic microsomes 
Quality 
Control 
Samples 
(QC) 
Nominal 
concentration 
(μM) 
Observed 
concentration  
(μM) 
Accuracy  
(% Difference) 
Precision  
(CV%) 
Intraday accuracy and precision 
QC1 10 9.82 ± 0.500 1.82 5.09 
QC2 1 1.01 ± 0.100 0.903 10.3 
QC3/LOQ 0.4 0.413 ± 0.0610 3.36 14.7 
Interday accuracy and precision 
QC1 10 9.64 – 10.2 1.52 – 3.57 2.89 – 6.21 
QC2 1 0.899 – 1.09 3.35 – 10.1 2.26 – 9.96 
QC3/LOQ 0.4 0.337 – 0.456 11.8 – 15.7 4.24 – 7.46 
QC = quality control standard, LOQ = limit of Quantitation 
 
 
 
Table 4.5: Inter-day (range over 3 days), and intra-day (mean ± S.D.) accuracy and 
precision values of 16α -OH testosterone following high performance liquid 
chromatography-ultraviolet detection in rat hepatic microsomes 
Quality 
Control 
Samples 
(QC) 
Nominal 
concentration 
(μM) 
Observed 
concentration  
(μM) 
Accuracy  
(% Difference) 
Precision 
(CV%) 
Intraday accuracy and precision 
QC1 20 19.2 ± 1.23 3.90 6.42 
QC2 10 10.4 ± 0.480 3.97 4.61 
QC3 1 1.08 ± 0.0903 7.66 8.39 
LOQ 0.4 0.364 ± 0.0264 9.02 7.26 
Interday accuracy and precision 
QC1 20 18.1 – 20.8 3.91 – 9.33 1.09 – 3.57 
QC2 10 10.3 – 10.6 2.84 – 5.96 3.95 – 5.84 
QC3 1 0.991 – 1.15 0.857 – 14.6 2.11 – 9.12 
LOQ 0.4 0.346 – 0.374 6.42 – 13.6 3.72 – 10.6 
QC = quality control standard, LOQ = limit of Quantitation 
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Table 4.6: Inter-day (range over 3 days), and intra-day (mean ± S.D.) accuracy and 
precision values of 2α -OH testosterone following high performance liquid 
chromatography-ultraviolet detection in rat hepatic microsomes 
Quality 
Control 
Samples 
(QC) 
Nominal 
concentration 
(μM) 
Observed 
concentration  
(μM) 
Accuracy (% 
Difference) 
Precision 
(CV%) 
Intraday accuracy and precision 
QC1 10 10.1 ± 0.552 0.669 5.48 
QC2 1 1.02 ± 0.0764 2.31 7.47 
QC3/LOQ 0.4 0.413 ± 0.0476 3.13 11.55 
Interday accuracy and precision 
QC1 10 9.64 – 10.3 2.35 – 3.55  3.20 – 6.19 
QC2 1 0.968 – 1.06 3.23 – 5.51 2.54 – 11.4 
QC3/LOQ 0.4 0.376 – 0.446 5.60 – 11.5 9.30 – 12.1 
QC = quality control sample, LOQ = limit of Quantitation 
 
 
 
 As demonstrated in Tables 4.4, 4.5 and 4.6, all three metabolites were 
detected with adequate inter and intraday accuracy and precision, as defined in 
section 3.2.3.3. 
 
4.1.2 Pre-incubation Time and Concentration Dependent (Irreversible) Inhibition of 
6β-, 16α- and 2α-OH Testosterone Formation in Pooled Rat Hepatic 
Microsomes by Secoisolariciresinol and Secoisolariciresinol Diglucoside  
To determine if SECO and SDG were irreversible inhibitors, each substrate 
was preincubated with pooled rat liver microsomes at various concentrations, and 
the effect on testosterone metabolism to 6β-, 16α- and 2α-OH testosterone was 
measured by HPLC.  Figure 4.2 indicates SECO inhibited testosterone metabolism 
to 6β-, 16α- and 2α-OH testosterone in a concentration-dependent manner.  
However, the duration of preincubation did not affect the percent of inhibition.  This 
data suggests SECO inhibited testosterone metabolism by reversible mechanisms. At 
2000 μM SECO inhibited 6β-, 16α- and 2α-OH testosterone formation by 36.2 ± 
2.81%, 65.7 ± 5.61% and 64.4 ± 5.56%, respectively. 
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Figure 4.2: The effect of increasing Secoisolariciresinol (SECO) concentration and 
preincubation time on the formation of a) 6β-, b) 16α- and c) 2α-OH testosterone, as 
determined by high performance liquid chromatography, in pooled male rat hepatic 
microsomes (n=4) following incubation with testosterone for 15 minutes.  Each 
point represents the mean of 3 replicates ± the standard deviation  
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Figure 4.3: The effect of increasing Secoisolariciresinol Diglucoside (SDG) 
concentration and preincubation time on the formation of a) 6β-, b) 16α- and c) 2α-
OH testosterone, as determined by high performance liquid chromatography, in 
pooled male rat hepatic microsomes (n=4) following incubation with testosterone for 
15 minutes.  Each point is the mean of 3 replicates ± the standard deviation 
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Figure 4.3 demonstrates that SDG does not affect testosterone metabolism to 
6β-, 16α- or 2α-OH testosterone in pooled male rat hepatic microsomes at any 
preincubation time with concentrations up to 1000 μM.   
 
4.1.3 Substrate and Inhibitor Concentration Dependent Inhibition of 6β-, 16α- or 2α-
OH Testosterone Formation by Secoisolariciresinol 
To determine the mechanism of reversible inhibition of 6β-, 16α- and 2α-OH 
testosterone formation by SECO, substrate (testosterone) and inhibitor 
concentrations were varied and incubated in pooled male rat liver microsomes.  At 
the substrate concentration equal to ½ KM (25 μM), substrate depletion was noted 
and interfered with the determination of inhibition.  Consequently, results from the 
lowest testosterone concentration were removed from the analysis.  At 50, 100 and 
250 μM testosterone, SECO caused a pronounced decrease in formation of 6β-OH 
testosterone, as demonstrated in Figure 4.4.   
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Figure 4.4: Secoisolariciresinol (SECO) concentration dependent inhibition of 6β-OH 
testosterone formation with 50, 100 or 250 μM testosterone in a 15 minute incubation with 
pooled (n=4) male, rat liver microsomes.  Each point represents the mean of 3 replicates ± the 
standard deviation 
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As indicated in Figure 4.5, at the substrate KM (50 μM), formation of 16α-
OH testosterone was increased in the presence of SECO.  However, the formation of 
16α-OH testosterone at 100 or 250 μM testosterone was not less than 80% of the 
control levels at any concentration of SECO.   
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Figure 4.5: Secoisolariciresinol (SECO) concentration dependent inhibition of 16α-
OH testosterone formation with 50, 100 or 250 μM testosterone in a 15 minute 
incubation with pooled (n=4) male, rat liver microsomes.  Each point represents the 
mean of 3 replicates ± the standard deviation 
 
 
Inhibition of 2α-OH testosterone formation was not decreased more than 
70% by SECO at 50, 100 or 250 μM testosterone, as shown in Figure 4.6.     
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Figure 4.6: Secoisolariciresinol (SECO) concentration dependent inhibition of 2α-
OH testosterone formation with 50, 100 or 250 μM testosterone in a 15 minute 
incubation with pooled (n=4) male, rat liver microsomes.  Each point represents the 
mean of 3 replicates ± the standard deviation 
 
 
Table 4.7: The percent of control activity for the formation of 6β-, 16α- and 2α-OH 
testosterone in pooled (n=4) rat liver microsomes by 1600 μM Secosiolariciresinol at 
the KM, 2KM and ~VMax concentration of testosterone 
 
 6β-OH 
testosterone 
16α-OH 
testosterone 
2α-OH 
testosterone 
Testosterone Concentration Percent Control Activity (mean ± S.D.) 
KM 29.0 ± 3.28 172 ± 14.0 86.0 ± 6.54 
2KM 31.8 ± 3.50 87.4 ± 4.51 75.0 ± 3.03 
VMax 42.4 ± 1.31 80.9 ± 4.17 71.9 ± 2.39 
VMax concentration = substrate concentration corresponding to enzyme saturation, KM = substrate 
concentration when half the available enzyme binding sites are occupied  
 
 
Table 4.7 indicates the degree of inhibition and activation of 6β-, 16α- and 
2α-OH testosterone formation at varying testosterone concentrations.  The KM, 2KM 
and ~VMax concentrations are 50, 100 and 250 μM. 
 To characterize the type of inhibition of 6β-OH testosterone formation by 
SECO, a Lineweaver-Burke plot was constructed (Figure 4.7).  This diagnostic plot 
indicated that SECO inhibition of 6β-OH testosterone formation did not follow 
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typical M-M kinetics, since the x-intercept, which corresponds to –KM, and the y-
intercept, which corresponds to 1/VMax, are not interpretable.      
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Figure 4.7: Lineweaver-Burke plot of the inverse relationship between substrate 
(testosterone) concentration and enzyme velocity at varying concentrations of 
Secosiolariciresinol (SECO) for 6β-OH testosterone formation.  Each point is the 
mean of 3 replicates 
 
 
4.2 Determination of a Method to Assess Induction of Cytochrome P450 and Phase 
II enzymes by Secoisolariciresinol Diglucoside and Secoisolariciresinol in 
Primary Rat Hepatocytes 
4.2.1 Optimized Primer Sets for Target Gene Amplification using Real-Time 
Reverse Transcription-Polymerase Chain Reaction 
To screen for the presence of transcriptional induction of phase I and II 
enzymes by real time RT-PCR, primers for target genes were designed.  Table 4.8 
lists these primer sequences, as well as the gene accession number, anticipated 
product size, amplification efficiency and control tissue, which was used to generate 
the standard curve.  A representative image of primer amplification products 
following gel electrophoresis is shown in Figure 4.8.   
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Figure 4.8: Separation of cytochrome P450 (CYP) 1A1, uridine diphosphate-
glucuronosyltransferase (UGT) 2B12, 2B3 and 2B1 real-time reverse transcription-
polymerase chain reaction amplification products by agarose gel electrophoresis.  
The molecular weight marker (shown on the right and left) has band sizes of 489, 
404, 353, 242, 190, 147 and 110 base pairs.  Each sample was run in duplicate with a 
non-template control sample (containing primers with no RNA) on the left 
 
 Figure 4.8 shows a sample agarose gel with separated PCR amplification 
products.  The CYP1A1 primers shown on the left have one amplification product, 
wherease two bands are visible in the lanes corresponding to the products amplified 
using CYP1A1 primers from Mar.  Additionally, the formation of a smaller primer-
dimer pair can be seen in the blank sample for UGT2B12.  Primers which formed 
multiple amplification products were not used.
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Table 4.8: Primer sequence, accession number, control tissue, product size, annealing temperature and efficiency (E) for optimized 
primer sets for target genes on the Cepheid SmartCycler real-time reverse transcription-polymerase chain reaction system using 
QIAGEN SYBR green real-time reverse transcription-polymerase chain reaction kits 
 
Gene 
name 
Control 
Tissue 
Accession 
Number 
Left primer 
(5’ Æ 3’) 
Right primer 
(3’ Æ 5’) 
Product 
size 
Annealing 
temp 
E 
Cytochrome P450 genes 
1A1 ♀ Lung NM_012540 ccc agc ctt cac atc agc ggt gtg gag cca ata cgg 237 57 1.92 
2B1 ♀ liver AF159245 ctc ctc ctt gct ctc ctc gt cct tgg tcc cag gtg tac tg 201 58 2.01 
2C11 ♂ liver Direct from 
paper 
ctg ctg ctg ctg aaa cac gtg cga tga cag cga tac tat cac 248 58 1.95 
2C13 ♂ liver NM_138514 gac agg gca ttg ctt tta gc gat gaa ttg ggg atc aca gc 210 55 2.15 
2D1 ♀ liver AB008442 agg tgg aga agg cca agg gcc tgg tct gtc atc tct gg 220 58 1.84 
2D2 ♀ liver AB008423 cca cct ctg tga cac ctt cg gca cct ctg cca tga agc 197 56 1.86 
3A1 ♀ liver NM_173144 gaa act gca gga gga gct cg cct ttg ggc ata aac aca cc 186 56 1.93 
3A2 ♂ liver NM_153312 tct tca tca tga ccc aca gc gct gga agg aga agt ttt gc 200 57 1.97 
GST genes 
A2 ♀ liver NM_017013 cat cgc cac caa ata tga cc ttc aaa ggc agg caa gta cc 190 58 1.88 
A5 ♀ liver NM_031509 gct ggt gca gac cag agc ccc agg ggg aat gta agg 154 59 1.96 
P1 ♀ liver NM_012577 gcc tgg gca tct gaa acc gag cca cat agg ca gaga gc 179 58 2.08 
UGT genes 
1A1 ♀ liver NM_012683 cca ttg tgg ccc agt acc ggg gga gta aac cac tct gc 186 59 1.88 
1A7 ♀ liver NM_130407 acc tct tca gcc cag tgt cc cgg agg cgt tga cat agg 156 57 2.13 
1A8 ♀ liver NM_175846 ggg tgg agt acg tga tga gg gac cct ttc ccc caa agc 186 58 2.00 
2B1 ♀ liver NM_173295 gac cga gcc gtc ttc tgg cca cac cta cca cac aga gc 142 58 2.13 
2B12 ♀ liver U06273 gct gag ata atg atg ggc aaa gc 
ttg acc cca gag aaa cc 196   57 2.10 
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4.2.2 Isolation and Culture of Rat Primary Hepatocytes: Method Development 
4.2.2.1 Hepatocyte Isolation Conditions 
To isolate and culture rat primary hepatocytes, proper surgical technique, 
digestion enzymes, buffers, flow and duration of perfusion were determined.     
 
4.2.2.1.1 Isolation of Rat Primary Hepatocytes 
To isolate rat primary hepatocytes, the liver was cleared of blood, the hepatic 
matrix was digested with enzymes and the cells dispersed and washed in buffer.  
Initial liver perfusions used EGTA to chelate calcium and increase matrix digestion.  
To prevent a temperature drop below cell survival, all buffers were warmed to 37°C 
and the liver was removed immediately following cannulation.  To replace calcium 
lost through the initial perfusion, CaCl2 was added to the digestion media.  A sterile 
cabinet was not required to ensure sterile cultures.  To prevent rupture of the liver 
due to pressure, the flow rate of perfusion was carefully maintained at 30 mL/min, 
the vena cava was nicked to allow perfusate outflow and heparin was injected into 
the vena cava to prevent blood clot formation.    
 
4.2.2.1.2 Hepatocyte Dissociation 
In order to isolate primary hepatocytes, the appropriate dissociation enzymes, 
flow rates and buffers were selected to breakdown the extracellular matrix and 
liberate the cells.  Cells isolated following perfusion with collagenase type II or III 
from Worthington did not result in adequate yield or viability.  Liberase blendzyme 
III, a digestion enzyme blend, was employed using the buffers outlined in section 
3.3.5.1.   
 
4.2.2.1.3 Viability and Cell Yield 
To plate rat primary hepatocytes, a viability >65% and a yield of >20 million 
cells was required.  To achieve this yield and viability, liver exposure to digestion 
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enzymes was kept under 10 minutes (by limited perfusion time and rinsing the liver 
of collagenase) and liver temperature was maintained at 37 °C.  Viability and yield 
vary with the digestion enzyme lot and pilot studies need to be conducted with each 
lot to determine concentration, duration of perfusion and flow rate. 
  
4.2.2.2 Hepatocyte Plating and Culturing 
The ideal duration of incubation for transcriptional activation of hepatocytes 
cultured on collagen-coated plates is 24 hours.  The plate size that would require the 
fewest viable cells but have sufficient amounts of RNA for real-time RT-PCR 
studies was determined.  Table 4.9 lists the different plate sizes and the number of 
cells needed for each plate size. 
 
Table 4.9: The number of wells per plate, diameter, growth area, media volume and 
number of cells per well for different plates used in cell culture  
Wells/plate Diameter
(mm) 
Growth Area
(cm2) 
Media Volume
(mL) 
Cells/well 
(x 106) 
6 35 9.6 3.4 1.92 
12 21 3.8 2 0.76 
24 16 2 1 0.4 
 
 
 
The average RNA yield from 35 mm and 21 mm plates was 15 μg and 5 μg, 
allowing for approximately 7500 and 2500 real-time RT-PCR runs respectively.  
Thus, 21 mm plates were acceptable for assessing induction of target genes. 
 
4.2.2.3 Hepatocyte Harvesting and RNA Isolation  
To determine upregulation of mRNA levels by inducers, primary cells were 
harvested and the RNA was isolated.   
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4.2.2.3.1 Harvesting of Primary Rat Hepatocytes 
The optimum harvesting method was determined for primary rat hepatocytes 
on collagen coated plates.  Difficulties in harvesting using a cell scraper or dispase 
II, and difficulties using Trizol for RNA isolation resulted in the use of RLT buffer 
(a component of QIAGEN RNeasy kits) to harvest cells. 
 
4.2.2.3.2 RNA Isolation from Primary Rat Hepatocytes 
RNA isolated from cells harvested with trizol resulted in an RNA yield and 
purity outside the acceptable range.  The low (1.0-1.1) purity ratio was likely due to 
contamination of the aqueous phase during the chloroform extraction.  Attempts to 
clean-up the RNA by re-extraction did not improve purity.  The use of double RNA 
extraction buffers and harvesting cells with RLT buffer gave adequate yield and 
purity. 
 
4.2.2.4 Verification of Hepatocyte Culture Conditions and Inducibility 
To determine if the hepatocyte culture conditions were appropriate for 
measuring mRNA induction, culture conditions were assessed for positive control 
induction and cell viability.  Positive control doses were tested for cytotoxicity after 
24 hours by the trypan blue exclusion test, following the method of Bajit et al.120.  
The positive control samples did not take up trypan blue more than the negative 
control group, in a blinded assessment, indicating cell survival following 24 hours 
incubation.  RNA yields from positive control test plates were compared with 
negative control samples.  Phenobarbital, DEX and βNF RNA yields were similar to 
the negative control group.  The fold induction of target gene expression by known 
inducers are listed in Table 4.10.  The total RNA yield obtained from tBHQ samples 
were 44% of the negative control samples.  Additionally, GSTA5 levels (as assessed 
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by real-time RT-PCR) were at least 100 fold lower.  Thus, only induction of CYP 
enzymes could be confirmed.    
 
Table 4.10: Positive control-fold induction of target genes based on real-time reverse 
transcription-polymerase chain reaction data from single plate experiments 
 Positive control [Final] μM Fold Induction 
CYP3A1 DEX 10 1.7 
CYP2B1 PB 100 2 
CYP1A1 PB 100 4 
 
 
Based on this information, the concentrations of DEX and PB used induced 
the CYP isoforms.  Phenobarbital is an inducer of CYP2B1 and 1A1, thus β-NF is 
not needed to cause induction of target CYP genes.  Both DEX and β-NF caused a 
decrease in CYP2B1 levels.   
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CHAPTER 5 
5. Discussion 
 This study screened for the presence of CYP3A2, CYP2B, and CYP2C11 
inhibition following exposure of male rat hepatic microsomes to the flaxseed 
lignans, SECO and SDG.  Furthermore, a rat primary hepatocyte isolation and 
culture system was designed to screen for the presence of CYP and Phase II enzyme 
induction by these compounds.  Secoisolariciresinol diglucoside did not inhibit the 
formation of 6β-, 16α- or 2α-OH testosterone.   
Secoisolariciresinol was a reversible inhibitor of 6β-OH testosterone 
formation (CYP3A) but Lineweaver-Burke plots did not identify the mechanism of 
reversible inhibition. However, SECO failed to inhibit 16α- and 2α-OH testosterone 
formation.  Interestingly, a concentration-dependent increase in 16α-OH testosterone 
formation (CYP2B/2C11) was observed at testosterone KM levels with no effect on 
2α-OH testosterone formation (CYP2C11).  The establishment of an isolation and 
culture procedure for rat primary hepatocytes allows for identification of SECO and 
SDG-mediated induction of CYP and/or Phase II enzymes in vitro.  Real-time RT-
PCR conditions were determined that could detect transcriptional changes in 
CYP1A1, 2B1, 2C11, 2C13, 2D1, 2D2, 3A1 and 3A2, GSTA2, A5 and P1, and 
UGT1A1, 1A7, 1A8, 2B1 and 2B12 genes.    
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5.1 Drug Interactions 
 Interactions between drugs and coadministered compounds are a major 
concern in the pharmaceutical industry.  The primary concern of drug interactions 
are increased toxicity, adverse side effects and decreased disease management.    
The FDA in the United States recommends that all new drugs be screened early in 
the development process for their ability to cause drug interactions115.   Drug 
interactions can occur at the PK or PD level.  The former is more common and 
involves any alteration in the absorption, distribution, metabolism and excretion of 
concomitant drugs121.  These can include changes in drug maximum concentration, 
time to maximum concentration, clearance, volume of distribution and half-life115.  
The most common type of PK based interactions involve drug metabolizing enzyme 
induction and inhibition115.  Typically, a preliminary screen of CYP enzyme 
interactions is the first step in predicting the potential for drug interactions115.  The 
FDA considers CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A as the major targets in 
humans for drug interactions115, although CYP2B interactions can be significant for 
toxic implications. 
Drug interactions resulting from CYP inhibition and induction can cause 
increased toxic metabolite formation and increased/decreased detoxification leading 
to altered circulatory drug concentrations.  Serious examples of adverse drug 
reactions, eg. torsades de pointes, rhabdomyolysis and ataxia, have occurred with 
certain CYP3A4 substrates and coadministered inhibitors121.  The abrupt removal of 
a natural product may lead to alterations in stable drug concentrations as well, 
resulting in potentially serious consequences122.   
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Phase II enzyme induction and inhibition is less often associated with 
negative drug interactions.  However, such interactions can also alter systemic drug 
concentrations and toxic metabolite production.  In vivo effects have been noted 
following administration of certain analgesics, nonsteroidal anti-inflammatory drugs, 
antivirals, anticonvulsants and benzodiazepines with drugs which inhibit UGT 
activity123.  Compounds which cause UGT induction have also influenced in vivo PK 
for these classes of drugs123.  For drug metabolizing enzyme activity modulations, 
the specific results depend on the nature of interaction, duration of exposure, and co-
administered drugs.  Until the establishment of the NHPD in Canada12, the public 
generally lacked knowledge about NHP interactions with drug metabolizing 
enzymes.   
Alterations of CYP metabolism can also impact disease states in the absence 
of pharmaceutical agents.  For instance, CYP2E1 metabolism can generate free 
radicals.  Agents which enhance CYP2E1 activity can lead to lipid peroxidation and 
a subsequent increase in free radical mediated diseases124.  Other CYPs are both up 
and down regulated in the presence of free radicals124.  Thus, altered metabolism can 
occur via increased free radicals, without direct protein interactions.  Internal 
homeostasis of fatty acids and steroids is in part governed by drug metabolizing 
enzyme levels.  Alterations in these enzymes can alter disease pathogenesis as 
well121. 
Unfortunately, drug metabolizing enzyme interactions are not always 
predictable for a number of reasons: location of interaction, interindividual 
differences and delayed onset of effect.  Interactions can occur at the hepatic or 
intestinal enzyme level93,125, depending on route of administration and substrate PK.  
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Cytochrome P450 enzymes, such as CYP3A4, have decreased activity in the elderly 
and patients with certain diseases121.  Interindividual differences, due to differential 
exposure to environmental inducers and inhibitors, occurs with both CYP and phase 
II enzymes2,49.  Certain drug interactions do not manifest immediately, even when 
the result of a PK interactions121, leading to missed adverse drug reaction diagnoses.  
Consequently, drug interactions involving the flaxseed lignans may not be identified 
as such.    
 
5.2 Drug Interactions Caused by Secoisolariciresinol and Secoisolariciresinol 
Diglucoside 
 Flaxseed has contributed to a number of adverse drug reaction cases in 
Canada since 1991, including two cases of suspected drug interactions126.  However, 
there is little information available on the mechanism of these interactions and there 
may be more cases of interactions that are unreported or misdiagnosed.  
Interestingly, there are no adverse drug interactions noted with flaxseed oil intake126.  
However, polyunsaturated fatty acids, almost 70% of the oil in flaxseed127, are now 
implicated in cardiac toxicity128.  Since flaxseed oil does not contain the lignans18, 
the lack of interactions observed with flaxseed oil is indicative of the role the lignans 
play in these interactions.   
A general dearth of information exists on the potential for flaxseed and the 
lignans to cause drug interactions.  Thus, the potential for SECO and SDG to inhibit 
or induce drug metabolizing enzymes was investigated.  The benefits of SECO 
and/or SDG are primarily in the treatment and/or prevention of diseases such as 
CVD, diabetes, and cancer18,19,23-30,129.  These patients are likely on other 
medications.  Type II diabetic medications include chlorpropamide, metformin and 
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rosiglitazone130, the latter being a CYP2C substrate131.  There are a myriad of drugs 
used in the treatment of CVD, including drugs which are angiotensin converting 
enzyme inhibitors, calcium channel blockers and statin drugs132.  The latter class of 
drugs include CYP3A substrates131 and CYP3A and 2B inducers8.  There are over 80 
FDA approved medications used in the treatment of cancer133.  Thus, the target 
population for flaxseed lignan benefits represent a particularly susceptible 
population to drug interactions, since they may be on any number or combination of 
medications.   
The PK of plant lignans is complex, and can affect absorption, distribution, 
metabolism and excretion of other compounds.  The two most likely sites of 
interactions caused by lignans are gastrointestinal absorption and gastrointestinal 
and/or hepatic metabolism.  The recirculation of lignans throughout the 
gastrointestinal system can prolong lignan exposure and increase the potential for 
drug interactions.  A preliminary screen to determine if lignans interact with key 
drug metabolizing enzymes is pertinent to predict the potential for drug interactions.       
 The in vivo liver and intestine concentrations are needed in order to 
determine the potential for plant lignans to cause enzyme interactions.  The 
concentration of SECO in the liver and intestine has not been clearly determined in 
humans or rats.  However, the liver and intestinal levels can be hypothesized from 
PK studies.  A human PK study using SDG indicated that the plasma maximum 
concentration of the mammalian lignans did not occur until 17 hours in males37.  
This lag time is likely due to passage through the gastrointestinal tract and 
conversion of SDG into the mammalian lignans.  However, it could also result from 
extensive enterohepatic circulation of SECO.  The estimated half-life of the 
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mammalian lignans is 4.4 to 12.6 hours; however, after 3 days less than 50% of the 
dose had been recovered as mammalian lignans in urine37.  Consequently, the 
remainder of the dose may remain as SECO in the intestinal or circulatory systems.   
Although the dose was only 78 μM on average37, a greater dose taken in an 
NHP, combined with nutritional sources, bioaccumulation and enterohepatic cycling 
indicate that SECO levels could be high enough to interact with intestinal or hepatic 
enzymes.  There is no evidence that SDG is absorbed intact and thus, it cannot 
interact with hepatic enzymes.  Flaxseed lignan PK will result in highest levels of 
SECO and SDG in the gastrointestinal tract.  Inhibition of CYP enzymes by SDG 
can only occur in the intestine.  Secoisolariciresinol can cause inhibition of CYP 
enzymes in the gastrointestinal tract or liver and will have the greatest impact on 
absorption by increasing the bioavailability of orally coadministered CYP substrates.  
Inhibition of hepatic and intestinal enzymes can also alter elimination through 
metabolism.   
 
5.3 Inhibition of Cytochrome P450 by Secoisolariciresinol and Secoisolariciresinol 
Diglucoside 
 Testosterone hydroxylation is an FDA approved115 in vitro method to assess 
the enzyme activity of various CYP isoforms.  In these experiments, the formation 
of 6β-, 16α- and 2α-hydroxytestosterone were monitored, corresponding to CYP3A, 
2B/2C11 and 2C11 mediated reactions in rats, respectively112.  The rat was chosen 
as a proxy for humans to screen for inhibition potential because CVD and diabetes 
disease models have been established26,27,29,30, they represent a more homogenous 
population57 and the PK of flaxseed and the lignans are similar between these 
species (See section 1.3.4.5 for more information).   
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5.3.1 Effects of Secoisolariciresinol Diglucoside on Cytochrome P450 Enzymes 
Secoisolariciresinol diglucoside did not decrease testosterone metabolite 
formation up to 1000 μM.  Consequently, SDG is not an inhibitor of CYP3A, 
2B/2C11 or 2C11 at physiologically relevant concentrations.  This is similar to 
results obtained elsewhere that indicate quercetin glycosides do not cause 
inhibition125.  Rutin and phlorizin, flavonoid glycosides, do not cause induction of 
CYP1A1134.   However, other glycosides, such as kaempferol glycosides isolated 
from Zingiber aromaticum135 and oleuropein glycoside isolated from olive oil136, 
inhibit CYP activity.  Naringin, a flavonoid glycoside found in grapefruit juice 
inhibits CYP3A1/2 in vivo137.   
Secoisolariciresinol diglucoside is broken down in the intestine into SECO 
by β-glucuronidase and β-glucosidase35.  There is no indication that SDG is taken up 
into systemic circulation.  Consequently, it is unlikely to reach the liver and cause 
inhibition.  Additionally, SDG may not be taken up into the cell intact to reach the 
active site of the CYP enzymes in vivo.  As indicated in Figure 1.1, SDG has two 
attached glucose molecules, causing it to be hydrophilic and contributing to its poor 
membrane permeability and absorption. 
 
5.3.2 Effects of Secoisolariciresinol on Cytochrome P450 Enzymes 
5.3.2.1 CYP3A Effects 
 Secoisolariciresinol demonstrated a concentration-dependent, reversible 
decrease in formation of 6β-hydroxytestosterone, corresponding to CYP3A in rats.  
According to the FDA, substrate concentrations around the KM more closely relate 
the IC50 to the inhibitory constant, Ki115.  At testosterone KM concentrations, the IC50 
of SECO is between 400 and 800 μM.  Precise determinations of inhibition 
mechanism and IC50 were not possible. 
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The mechanism of reversible inhibition observed for 6β-OH testosterone 
formation could not be determined for several reasons.  Certain CYP isoforms may 
not exhibit typical M-M kinetics, particularly CYP3A138.  The Lineweaver-Burk plot 
(Figure 4.7) showed a shift to the right such that the lines failed to intersect the y-
axis with the appropriate sign.  Therefore, the x-intercept did not correspond to -
1/KM and the y-intercept did not correspond to 1/VMax.  However, the overall pattern 
of the lines closely resembled those observed with competitive inhibition.   
One of the primary difficulties in determining the mechanism of reversible 
inhibition was the substrate depletion observed at low substrate concentrations.  In 
order for studies to be valid, there should be no less than 10% substrate depletion, 
even for substrates with a low KM115.  Unfortunately, testosterone substrate depletion 
was observed at ½KM values, making the data obtained from these experiments 
unusable in determining inhibition constants.  The fact that testosterone is 
metabolized by multiple CYPs simultaneously in a microsomal system may have 
caused this depletion.  Additionally, incubation time and protein concentration 
required for linear testosterone metabolite formation were not determined.  
Experimental design was based upon literature values for this general screen.  
Experimental error alone cannot explain the significant substrate depletion, but may 
have contributed.  Non-specific protein binding occurs with numerous compounds.  
It primarily involves binding to phospholipids found in microsomes139.  This effect 
may have decreased testosterone concentrations at the enzyme active site, leading to 
substrate depletion.  
The ratio of inhibitor concentration ([I]) to Ki is indicative of in vivo 
inhibition potential115.  The inhibition constant Ki is specific to the mechanism of 
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reversible inhibition, which could not be determined for SECO inhibition of 
CYP3A.  The IC50 lies between 400 and 800 μM at testosterone KM levels, which is 
quite high compared to in vivo inhibitors.  For competitive inhibitors, the Ki can be 
related to the IC50 as follows80: 
                 Equation 5.1 
This equation gives an approximate estimate of Ki for CYP3A inhibition by SECO.  
Using the data obtained at substrate KM levels (50 μM), the Ki is half the IC50 value, 
or between 200 and 400 μM.  Grapefruit juice, an oft noted gastrointestinal CYP3A 
inhibitor and contributor to drug interactions, is categorized as a moderate CYP3A 
inhibitor115.  The Ki for competitive inhibition of CYP3A by bergamottin, one of the 
inhibitory compounds in grapefruit juice, is 13 μM77.     
 
Table 5.1: Prediction of in vivo inhibition based on in vitro reversible inhibition 
constants115 
[I]/Ki Prediction
> 1 Likely 
0.1 < [I]/Ki < 1 Possible 
< 0.1 Remote 
     
 
 As mentioned previously, the average dose of lignans in in vivo studies was 
only 78 μM.  Given the high Ki and IC50 compared to other known natural product 
inhibitors, and the ratio of SECO concentration to Ki, in vivo inhibition is unlikely 
according to the relationship between Ki and inhibitor concentration listed in Table 
5.1.  A larger dose of lignans would increase the potential for purified lignans to 
cause in vivo effects.     
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 The degree of CYP3A inhibition by SECO observed in this study indicated it 
is unlikely to cause serious problems with coadministered drugs.  However, sensitive 
CYP3A substrates such as midazolam, saquinavir and simvastatin115 are the most 
likely to be affected.  These drugs have a greater than 5 fold increase in systemic 
concentration following administration of a CYP inhibitor115.  Drugs that undergo 
extensive first pass metabolism likely fall into the category of sensitive CYP 
substrates.  Additionally, CYP3A substrates with narrow therapeutic ranges, 
including cyclosporine, fentanyl and quinidine115, are also susceptible to in vivo 
interactions via decreased enzyme activity.       
 
5.3.2.2 CYP2B and CYP2C11 Effects 
 Secoisolariciresinol did not inhibit 16α- or 2α-OH testosterone formation at 
any substrate concentration.  However, a concentration-dependent increase in 16α-
OH testosterone formation alone was observed at testosterone KM levels.  Since 16α-
OH testosterone corresponds to CYP2B/2C11 activity and 2α-OH testosterone 
corresponds to CYP2C11 activity, this implies that SECO increased CYP2B activity, 
and did not affect CYP2C11.   
Activation of CYP2B-mediated testosterone hydroxylation by SECO could 
be an example of heterotropic cooperativity.  This type of enhanced activity is most 
commonly observed in CYP3A and can be the result of allosteric interactions140, 
although multiple binding sites have not been characterized for CYP2B.  Recent 
evidence suggests heteroactivation could be the result of a sequential, multistep 
process involving the inhibitor141, thus, a lack of multiple binding sites does not 
preclude the possibility of CYP2B activation.  Heteroactivation of CYP1A1 by tea 
polyphenols shows an increase in activity less than 2 fold, followed by a 
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concentration-dependent inhibition exhibited in the mM range of inhibitor142.   
CYP2B activity showed a similar pattern of activation by SECO as that seen with 
CYP1A1 in the presence of epicatechin, a proposed heteroactivator142.  It is possible 
that SECO causes heteroactivation of CYP2B but inhibition does not occur below 2 
mM SECO.  Heteroactivation could cause in vivo effects which resemble those seen 
with enzyme induction, however, the consequences would occur much faster since 
protein synthesis is not required140.  The evidence for cooperativity in vivo is 
inconclusive, but is most likely for CYP3A4140.  Tangeretin activates CYP3A4 
activity in human microsomes, but shows no effects in vivo143.   
 The effect of natural compounds on CYP2B activity has been largely 
ignored, since the majority of current pharmaceuticals are not eliminated via this 
isoform.  In fact, the FDA does not require CYP2B inhibition assessments unless 
there is compelling supporting evidence115.  Consequently, there is a dearth of 
information available on natural compound effects on this isoform.  CYP2B has the 
potential to bioactivate a variety of compounds.  Polychlorinated biphenyl 
compounds, carcinogenic environmental contaminants, are bioactivated by rat and 
human CYP2B144.  The activation of CYP2B could lead to increased carcinogenesis 
of polychlorinated biphenyls and other compounds.  The activation of CYP2B 
metabolism of procarcinogens would be a negative consequence of SECO 
administration, and needs to be investigated further.  
 
5.4 Relevance of Inhibition Results 
In order to predict in vivo drug interactions arising from natural product 
inhibition of CYP isoforms, a variety of models have been proposed.  However, 
these are dependent on the identification of all inhibitory compounds present in a 
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preparation145.  With many natural products, this identification can be a major 
confounding factor in determining drug interaction potential.  Flaxseed contains the 
plant lignan SDG, which can be converted into SECO, followed by the mammalian 
lignans.  It also contains various oils and stabilizers, which can contribute to drug 
metabolizing enzyme activity.  Herbacetin diglucoside is also present as a polymer 
in the plant146.  The presence of multiple compounds in the gastrointestinal tract 
and/or liver makes in vivo predictions from in vitro data on a single compound 
challenging.  However, the likelihood of relevant inhibition increases in the presence 
of multiple compounds145.   
There are several limitations to examining CYP inhibition in rat liver 
microsomes.  The two predominant limitations are in vitro to in vivo extrapolations 
and species differences in enzymes.  A preliminary screen indicating CYP inhibition 
and activation of rat enzymes supports the need for further research into human 
enzyme interactions by SECO.  The relationship between human and rat CYPs is 
well characterized, although not always predictable.  However, the inhibition of rat 
CYP enzymes indicates the probability of human enzyme interactions.  
Pharmaceutical companies, such as Merck Frosst, use the rat as a test species when 
investigating the effects of new compounds on CYP enzymes117. 
As the knowledge of CYP inhibition based drug interactions by natural 
products increases, so does the ability to use in vitro data to predict in vivo 
significance.  For example, garlic microsomal inhibition data correlates with known 
systemic effects147.  However, results from studies with Ginkgo biloba show a lack 
of agreement between studies148.  Research continues to determine the cause for 
discrepancies between studies.  Reasons for differences between in vitro and in vivo 
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studies with flavonoids include protein binding, poor membrane permeability, 
inactivation via metabolism, interindividual variation in absorption, product 
variability and variability in product dissociation143.  In order to use CYP inhibition 
results obtained in vitro to predict in vivo drug interactions, further studies are 
needed to determine protein binding, membrane permeability, etc.  The relationship 
between in vivo effects from in vitro CYP inhibitors is most accurate when based on 
the maximum unbound concentration of inhibitor in hepatic inlet blood flow149.  
Until hepatic concentrations of SECO are known, through protein binding and in 
vivo PK studies, the relationship between in vitro effects and in vivo drug interaction 
potential remains unknown.        
Additional confounding factors in drug inhibition potential occur with 
different test systems.  In microsomes, the absence of intact membranes is one of the 
major differences between in vitro and in vivo effects of an inhibitor.  The lack of 
intact membranes and transporters allow for access to the enzyme active site for all 
compounds.  Not all compounds reach high concentrations in cells due to solubility 
and transport across membranes.  Thus, compounds may be identified as inhibitors 
which do not have access to proteins in a cell.  Conversely, some inhibitors may 
decrease transporter activity, leading to decreased uptake of substrates.  These 
inhibitors will not be identified in a microsomal system, and may lead to significant 
in vivo interactions.  Secoisolariciresinol is a known substrate of CYP enzymes38.  
Metabolites of SECO may cause inhibition of CYP activity.  However, it is not 
metabolized by CYP enzymes to a great extent in vivo3.  The difference between in 
vitro and in vivo metabolism of SECO has not been clearly determined, and may 
 81
represent an additional factor to consider when extrapolating microsomal studies to 
drug interaction potential.     
 
5.5 Development of a Rat Primary Hepatocyte Culture System 
The development of a method to screen for drug metabolizing enzyme 
induction in vitro is critical to determining the potential for drug interactions.  In 
vivo interactions with natural products have occurred with St. John’s wort, garlic, 
Ginkgo biloba and American Ginseng122.  In vitro screening methods are 
implemented to quickly determine the potential for new compounds to cause 
interactions.  This information can be modelled to determine the potential for in vivo 
effects.  One of the best models is primary hepatocytes, which are functional, living 
cells.  Primary hepatocytes are the closest in vitro mimic of in vivo conditions45,57,150, 
and are able to detect the potential for drug metabolizing enzymes to undergo 
biphasic and opposed effects (dose dependent induction or inhibition) by natural 
products151.  This was observed with Ginkgo biloba and CYP1A2 and 2D6151.      
Transcriptional upregulation is a common method of induction.  The use of 
real-time RT-PCR to screen for induction can lead to false positives but the FDA 
considers mRNA measurements the preferred screening method when there is the 
potential for simultaneous enzyme induction and inhibition115.  Since preliminary 
studies indicated that SECO was an inhibitor of CYP isoforms, quantitation of 
mRNA levels are optimal for screening for induction potential.  This removes the 
potential for missing induction due to concurrent inhibition of enzymes.  The target 
genes, CYP1A1, 1A2, 2B1, 2C11, 2C13, 2D1, 2D2, 3A1 and 3A2, GSTA2, A5 and 
P1, and UGT1A1, 1A7, 1A8, 2B1 and 2B12, can be quantified for mRNA levels 
following exposure to SECO and SDG using real-time RT-PCR.  Assessment of 
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enzyme induction via real-time RT-PCR should not be considered exhaustive.  
Compounds which cause increased activity via decreased protein degradation, 
increased protein stabilization, or interaction upstream of the transcription factor, 
such as the effects of Keap-1 phosphorylation on the induction of genes under the 
control of the ARE58 will not be idenitifed.      
The mechanism of action by which flaxseed lignans are beneficial in the 
treatment of many diseases remains elusive. Induction of phase II enzymes, 
particularly UGT, may alter endogenous steroid metabolism, and this in part may 
explain lignans’ purported benefit in the protection of certain forms of cancer49.  
Induction of phase II enzymes can also decrease cancer risk by increased 
detoxification of carcinogens.  The induction of drug metabolizing enzymes by 
lignans can increase detoxification of carcinogens, alter fatty acid metabolism and 
otherwise readjust internal homeostasis.  This induction may be the beneficial 
mechanism in lignan effective diseases. 
A rat primary hepatocyte culture was established for which positive control 
samples demonstrated the potential for induction.  The establishment of this primary 
cell culture system based on literature information was difficult.  For hepatocyte 
isolation, I found that information was insufficient in terms of media type, perfusion 
duration and flow rate.  The most complicated aspect involved the use of collagenase 
for dissociation.  These enzymes have different activity depending on the 
commercial source, and this caused viability and yield problems when using 
literature protocols. 
To determine induction by positive control compounds, I encountered several 
difficulties with t-BHQ and the trypan blue exclusion test.  The use of t-BHQ as a 
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positive control standard for GST induction at literature concentrations appeared to 
cause cytotoxicity in multiple tests.  However, all positive control compound 
concentrations were assessed for cell death via trypan blue exclusion.  These tests 
did not indicate t-BHQ caused cell death more than negative controls.  
Consequently, no positive control for GST induction was identified. 
The determination of real-time RT-PCR primers for target genes using 
SYBR green chemistry resulted in a consistent systematic method.  As opposed to 
the use of Taqman probes, the use of SYBR green chemistry reduced optimization 
time and cost.  SYBR green can be used to detect amplification of any target genes, 
whereas Taqman probes require different probes to be generated for each target. 
The major limitation of this project was the examination of SECO and SDG 
alone.  The mammalian lignans ENL and END are present in the liver and undergo 
enterohepatic circulation.  Thus, the drug interaction potential of flaxseed, SDG and 
SECO cannot be predicted without information on ENL and END and the capacity 
of these mammalian lignans to induce and/or inhibit Phase I and II enzymes.  This is 
a complicating factor when examining many NHPs.  The mammalian lignans may 
influence systemic drug concentrations and other PK parameters via induction and 
inhibition of CYP and phase II genes.   
The target genes chosen for the preliminary screen of enzyme induction by 
SECO and SDG did not include transporters.  Transporters are a known cause of in 
vivo drug interactions.  Transporters are often under the control of the transcription 
factors used to induce CYP and phase II enzymes.  Thus, co-induction usually 
occurs with transporters and drug metabolizing enzymes.  However, this is not 
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always true.  The lack of screening for transporter induction by SECO and SDG 
could overlook a potential source of drug interactions.   
Overall, the major limitations of this study were the examination of SECO 
and SDG only and the examination of induction of CYP and phase II enzymes, 
without the inclusion of transporters.  Thus, the presence of drug metabolizing 
enzyme induction would support further studies, but a lack of induction would not 
preclude the possibility of drug interactions.  Drug interactions can occur via the 
mammalian lignans or through transporter induction or inhibition.  
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CHAPTER 6 
6. Conclusions and Perspectives 
 Secoisolariciresinol caused a reversible, concentration dependent decrease in 
6β-OH testosterone formation, a marker of CYP3A activity, in rat liver microsomes.  
Additionally, SECO caused a reversible, concentration dependent increase in 16α-
OH testosterone at testosterone KM levels without an increase in 2α-OH testosterone 
formation.  This indicates that SECO is an activator of CYP2B activity.  
Secoisolariciresinol diglucoside was not an inhibitor of 6β-, 16α-, or 2α-OH 
testosterone formation.  A rat primary hepatocyte culture and real-time RT-PCR 
conditions were established that could measure transcriptional induction of target 
CYP, UGT and GST genes.  This method will allow the screening of SECO and 
SDG potential induction and subsequent drug interactions. 
 More studies are needed to determine the mechanisms by which SECO 
inhibits CYP3A and activates CYP2B in rats.  The ability of SECO to cause enzyme 
inhibition in humans also requires further examination.  Since SECO is an inhibitor 
of certain CYP enzymes, further studies are needed to completely characterize the 
inhibition profile of this compound.  The ultimate step is to determine the in vivo 
potential for inhibition of CYP metabolism of a coadministered substrate. 
 The ability of SECO and SDG to cause enzyme induction requires 
examination in rat primary hepatocytes.  The results from these studies will dictate 
the direction of future research.  The final step in the characterization of lignan 
effects on drug metabolizing enzymes involves the characterization of END and 
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ENL as inhibitors and inducers.  All this information is needed to determine the 
safety of lignan use. 
This information is more pertinent than ever, since Beneflax, a lignan 
supplement containing at least 35% SDG, has recently received FDA approval for 
use in human subjects152.  The knowledge of lignan-drug metabolizing enzyme 
interactions is critical to determining product safety, particularly when used in 
conjunction with other compounds. 
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